<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="129bfea5-3564-4989-846b-b79a17a5545b"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use SUNLENCA safely and effectively. See full prescribing information for SUNLENCA.<br/>
      <br/> SUNLENCA<sup>®</sup> (lenacapavir) tablets, for oral use<br/> SUNLENCA<sup>®</sup> (lenacapavir) injection, for subcutaneous use<br/> Initial U.S. Approval: 2022</title>
   <effectiveTime value="20250326"/>
   <setId root="e5652804-29c4-40d7-aeb2-0142ed2a7b5b"/>
   <versionNumber value="7"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="185049848" root="1.3.6.1.4.1.519.1"/>
            <name>Gilead Sciences, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="3458afcc-dbcd-4601-85c3-bede0b1b9ae2"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20241125"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="61958-3001" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Sunlenca</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>LENACAPAVIR SODIUM</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="300" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="BDT58WJ9WE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LENACAPAVIR SODIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="A9A0O6FB4H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LENACAPAVIR</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="D9C330MD8B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>COPOVIDONE K25-31</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="TUF2IVW3M2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLOXAMER 407</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Y4S76JWI15" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="4" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="1" unit="1"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="61958-3001-1" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="active"/>
                                             <effectiveTime>
                                                <low value="20221222"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="5" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="1" unit="1"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="61958-3001-2" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="active"/>
                                             <effectiveTime>
                                                <low value="20221222"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="4" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="61958-3001-3" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20241113"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA215974" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20221222"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48332" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BROWN" xsi:type="CE">
                              <originalText>Beige</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="21" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">GSI;62L</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="61958-3002" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Sunlenca</name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>LENACAPAVIR SODIUM</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="61958-3002-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20221222"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator value="3" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="61958-3004" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Sunlenca</name>
                              <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>LENACAPAVIR SODIUM</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIM">
                                 <quantity>
                                    <numerator value="463.5" unit="mg"/>
                                    <denominator value="1.5" unit="mL"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="BDT58WJ9WE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LENACAPAVIR SODIUM</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="A9A0O6FB4H" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>LENACAPAVIR</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="5655G9Y8AQ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYETHYLENE GLYCOL 300</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>WATER</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="1.5" unit="mL"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="61958-3004-1" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 1: Convenience Kit of Co-Package" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA215973" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250318"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA215973" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20221222"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="61958-3005" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Sunlenca</name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>LENACAPAVIR SODIUM</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="61958-3005-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250318"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator value="3" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="61958-3004" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Sunlenca</name>
                              <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>LENACAPAVIR SODIUM</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIM">
                                 <quantity>
                                    <numerator value="463.5" unit="mg"/>
                                    <denominator value="1.5" unit="mL"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="BDT58WJ9WE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LENACAPAVIR SODIUM</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="A9A0O6FB4H" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>LENACAPAVIR</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="5655G9Y8AQ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYETHYLENE GLYCOL 300</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>WATER</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="1.5" unit="mL"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="61958-3004-1" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 1: Convenience Kit of Co-Package" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA215973" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250318"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA215973" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250318"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="b92a2aab-d723-456d-958d-61b73aa3e3b3"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20241125"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorule">
                           <col width="60%" align="left" valign="top"/>
                           <col width="40%" align="right" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>Dosage and Administration (<linkHtml href="#S2.1">2.1</linkHtml>, <linkHtml href="#S2.3">2.3</linkHtml>, <linkHtml href="#S2.4">2.4</linkHtml>)</td>
                                 <td>11/2024</td>
                              </tr>
                              <tr>
                                 <td>Warnings and Precautions (<linkHtml href="#S5.3">5.3</linkHtml>)</td>
                                 <td>11/2024</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="672ace4d-1aac-46c4-9407-623bd1c1579e"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>SUNLENCA, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 whose current antiretroviral regimen is failing due to resistance, intolerance, or safety considerations.</paragraph>
               </text>
               <effectiveTime value="20241125"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>SUNLENCA, a human immunodeficiency virus type 1 (HIV-1) capsid inhibitor, in combination with other antiretroviral(s), is indicated for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 whose current antiretroviral regimen is failing due to resistance, intolerance, or safety considerations. (<linkHtml href="#S1">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="8bf6f307-19dd-4081-bcde-157e2a409a87"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20241125"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Recommended dosage – Initiation with one of two options followed by once every 6 months maintenance injection dosing. Tablets may be taken without regard to food. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                        </list>
                        <table width="100%">
                           <col width="25%" align="left" valign="middle"/>
                           <col width="75%" align="left" valign="middle"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">Initiation Option 1</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Day 1</td>
                                 <td styleCode="Rrule">927 mg by subcutaneous injection (2 × 1.5 mL injections)<br/>600 mg orally (2 × 300 mg tablets)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Day 2</td>
                                 <td styleCode="Rrule">600 mg orally (2 × 300 mg tablets)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">Initiation Option 2</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Day 1</td>
                                 <td styleCode="Rrule">600 mg orally (2 × 300 mg tablets)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Day 2</td>
                                 <td styleCode="Rrule">600 mg orally (2 × 300 mg tablets)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Day 8</td>
                                 <td styleCode="Rrule">300 mg orally (1 × 300 mg tablet)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Day 15</td>
                                 <td styleCode="Rrule">927 mg by subcutaneous injection (2 × 1.5 mL injections)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">Maintenance</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" colspan="2">927 mg by subcutaneous injection (2 × 1.5 mL injections) every 6 months (26 weeks) from the date of the last injection +/-2 weeks.</td>
                              </tr>
                           </tbody>
                        </table>
                        <list listType="unordered" styleCode="disc">
                           <item>Planned missed injections: If scheduled injection is to be missed by more than 2 weeks, SUNLENCA tablets may be used for oral bridging for up to 6 months until injections resume. Recommended dosage is 300 mg orally once every 7 days. (<linkHtml href="#S2.3">2.3</linkHtml>)</item>
                           <item>Unplanned missed injections: If more than 28 weeks since last injection and tablets have not been taken for oral bridging, restart initiation from Day 1 (using Option 1 or Option 2) if clinically appropriate. (<linkHtml href="#S2.3">2.3</linkHtml>)</item>
                           <item>SUNLENCA injection is for subcutaneous administration only. Two 1.5 mL injections are required for complete dose. (<linkHtml href="#S2.4">2.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="86cad6ed-0ff5-40b8-9eec-5439cc8c17f3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1	Adherence to Treatment Regimen</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Prior to starting SUNLENCA, healthcare providers should carefully select patients who agree to the required every 6 month injection dosing schedule and counsel patients about the importance of adherence to scheduled SUNLENCA dosing visits and concomitant oral antiretroviral therapy to help maintain viral suppression and reduce the risk of viral rebound and potential development of resistance with missed doses <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>, <linkHtml href="#S12.4">Microbiology (12.4)</linkHtml>]</content>.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="53773802-20e4-4e47-9b53-9533fc761c72"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2	Recommended Dosage</title>
                     <text>
                        <paragraph>SUNLENCA can be initiated using one of the two recommended dosage regimens in <linkHtml href="#table1">Table 1</linkHtml> and <linkHtml href="#table2">Table 2</linkHtml> below. Maintenance dosing is administered by subcutaneous injection every 6 months regardless of the initiation regimen. Healthcare providers should determine the appropriate initiation regimen for the patient. SUNLENCA oral tablets may be taken with or without food <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                        <table width="90%" ID="table1">
                           <caption>Table 1	Recommended Treatment Regimen for SUNLENCA Initiation and Maintenance, Option 1</caption>
                           <col width="25%" align="center" valign="middle"/>
                           <col width="75%" align="center" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule" align="left">Treatment Time</th>
                                 <th styleCode="Rrule"/>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule"/>
                                 <td styleCode="Rrule">
                                    <content styleCode="bold">Dosage of SUNLENCA: Initiation</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Day 1</td>
                                 <td styleCode="Rrule">927 mg by subcutaneous injection (2 × 1.5 mL injections)<br/>600 mg orally (2 × 300 mg tablets)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Day 2</td>
                                 <td styleCode="Rrule">600 mg orally (2 × 300 mg tablets)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule"/>
                                 <td styleCode="Rrule">
                                    <content styleCode="bold">Dosage of SUNLENCA: Maintenance</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Every 6 months (26 weeks) <footnote>From the date of the last injection.</footnote> +/-2 weeks</td>
                                 <td styleCode="Rrule">927 mg by subcutaneous injection (2 × 1.5 mL injections)</td>
                              </tr>
                           </tbody>
                        </table>
                        <table width="90%" ID="table2">
                           <caption>Table 2	Recommended Treatment Regimen for SUNLENCA Initiation and Maintenance, Option 2</caption>
                           <col width="25%" align="center" valign="middle"/>
                           <col width="75%" align="center" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule" align="left">Treatment Time</th>
                                 <th styleCode="Rrule"/>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule"/>
                                 <td styleCode="Rrule">
                                    <content styleCode="bold">Dosage of SUNLENCA: Initiation</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Day 1</td>
                                 <td styleCode="Rrule">600 mg orally (2 × 300 mg tablets)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Day 2</td>
                                 <td styleCode="Rrule">600 mg orally (2 × 300 mg tablets)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Day 8</td>
                                 <td styleCode="Rrule">300 mg orally (1 × 300 mg tablet)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Day 15</td>
                                 <td styleCode="Rrule">927 mg by subcutaneous injection (2 × 1.5 mL injections)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule"/>
                                 <td styleCode="Rrule">
                                    <content styleCode="bold">Dosage of SUNLENCA: Maintenance</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Every 6 months (26 weeks) <footnote>From the date of the last injection.</footnote> +/-2 weeks</td>
                                 <td styleCode="Rrule">927 mg by subcutaneous injection (2 × 1.5 mL injections)</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="ff9d41b7-62bd-485e-a202-9a485d92bb0c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3	Recommended Dosing Schedule for Missed Dose</title>
                     <effectiveTime value="20241125"/>
                     <component>
                        <section>
                           <id root="6b9ebf6f-d12f-444d-9507-741f2578831b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold xmChange">Planned Missed Injections</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="xmChange">During the maintenance period, if a patient plans to miss a scheduled 6-month injection visit by more than 2 weeks, SUNLENCA tablets may be taken for up to 6 months until injections resume. Refer to Table 3 below for the recommended dosage after planned missed injections.</content>
                              </paragraph>
                              <table width="90%" ID="table3">
                                 <caption>Table 3	Recommended Dosage after Planned Missed Injections: Weekly Oral Maintenance</caption>
                                 <col width="30%" align="left" valign="top"/>
                                 <col width="70%" align="left" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">
                                          <content styleCode="xmChange">Time since Last Injection</content>
                                       </th>
                                       <th styleCode="Rrule">Recommendation</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="xmChange">26 to 28 weeks</content>
                                       </td>
                                       <td styleCode="Rrule">Maintenance oral dosage of 300 mg taken once every 7 days for up to 6 months. <br/>Resume the maintenance injection dosage within 7 days after the last oral dose.</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20241125"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2d424372-ba4e-4b31-861b-38640108d818"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold xmChange">Unplanned Missed Injections</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="xmChange">Patients who miss a scheduled injection visit should be clinically reassessed, including consideration of lenacapavir resistance testing, to ensure resumption of therapy remains appropriate. During the maintenance period, if more than 28 weeks have elapsed since the last injection and SUNLENCA tablets have not been taken, see Table 4 below for the recommended dosage after unplanned missed injections. Adherence to the injection dosing schedule is strongly recommended <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml> and <linkHtml href="#S12.4">Microbiology (12.4)</linkHtml>]</content>.</content>
                              </paragraph>
                              <table width="90%">
                                 <caption>Table 4 	Recommended Dosage after Unplanned Missed Injections</caption>
                                 <col width="30%" align="left" valign="top"/>
                                 <col width="70%" align="left" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">
                                          <content styleCode="xmChange">Time since Last Injection</content>
                                       </th>
                                       <th styleCode="Rrule">Recommendation</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="xmChange">More than 28 weeks</content>
                                       </td>
                                       <td styleCode="Rrule">Reinitiate with Option 1 (Table 1) or Option 2 (Table 2) and then continue with maintenance injection dosing.</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20241125"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="85c3b6d7-3c2e-473d-bc51-6fe25f6f3c42"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4	Preparation and Administration of Subcutaneous Injection</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">SUNLENCA injection is only for subcutaneous administration into the abdomen by a healthcare provider. Do NOT administer intradermally due to risk of serious injection site reactions <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>].</content>
                           </content>
                        </paragraph>
                        <paragraph>Use aseptic technique. Visually inspect the solution in the vials and prepared syringe for particulate matter and discoloration prior to administration. SUNLENCA injection is a yellow solution. Do not use SUNLENCA injection if the solution is discolored or if it contains particulate matter. Once the solution is withdrawn from the vials, the subcutaneous injections should be administered as soon as possible <content styleCode="italics">[see <linkHtml href="#S16">How Supplied/Storage and Handling (16)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">There are two available injection kits, which differ only in how SUNLENCA injection is prepared (the components and associated method for withdrawal of the solution from the vials) <content styleCode="italics">[see <linkHtml href="#S16">How Supplied/Storage and Handling (16)</linkHtml>]</content>. Refer to the figures below for the relevant injection kit.</content>
                        </paragraph>
                        <paragraph>The injection kit components are for single use only. Two 1.5 mL injections are required for a complete dose.</paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                     <component>
                        <section>
                           <id root="1ed56502-8ffd-495f-8ae4-79a462048f0d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics underline xmChange">Vial access device injection kit</content>
                              </paragraph>
                              <paragraph>Figure 1 identifies the components for use in the administration steps for the vial access device injection kit, and the administration steps are provided in Figure 2. Use of a vial access device is required in this kit.</paragraph>
                              <paragraph>
                                 <content styleCode="xmChange bold">Figure 1	SUNLENCA Vial Access Device Injection Kit Components</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="xmChange">
                                    <renderMultiMedia referencedObject="MM1"/>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="xmChange">
                                    <content styleCode="bold">Figure 2	SUNLENCA Injection Steps for Vial Access Device Injection Kit</content>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="xmChange">
                                    <renderMultiMedia referencedObject="MM2"/>
                                 </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241125"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="871934af-2294-44f6-90c1-e72917071932"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics underline xmChange">Withdrawal needle injection kit</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="xmChange">Figure 3 identifies the components for use in the administration steps for the withdrawal needle injection kit, and the administration steps are provided in Figure 4. The 18-gauge needle is for withdrawal only in this kit.</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="xmChange bold">Figure 3	SUNLENCA Withdrawal Needle Injection Kit Components</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="xmChange">
                                    <renderMultiMedia referencedObject="MM3"/>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="xmChange">
                                    <content styleCode="bold">Figure 4	SUNLENCA Injection Steps for Withdrawal Needle Injection Kit</content>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="xmChange">
                                    <renderMultiMedia referencedObject="MM4"/>
                                 </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241125"/>
                           <component>
                              <observationMedia ID="MM1">
                                 <text>Figure 1</text>
                                 <value xsi:type="ED" mediaType="image/jpeg">
                                    <reference value="sunlenca-01.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                           <component>
                              <observationMedia ID="MM2">
                                 <text>Figure 2</text>
                                 <value xsi:type="ED" mediaType="image/jpeg">
                                    <reference value="sunlenca-02.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                           <component>
                              <observationMedia ID="MM3">
                                 <text>Figure 3</text>
                                 <value xsi:type="ED" mediaType="image/jpeg">
                                    <reference value="sunlenca-03.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                           <component>
                              <observationMedia ID="MM4">
                                 <text>Figure 4</text>
                                 <value xsi:type="ED" mediaType="image/jpeg">
                                    <reference value="sunlenca-04.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="9ac8fd2a-e734-48dd-a0e2-f21bdc63c9f5"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <effectiveTime value="20241125"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets: 300 mg</paragraph>
                        <paragraph>Injection: 463.5 mg/1.5 mL (309 mg/mL) in single-dose vials. (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section>
                     <id root="7bd2e691-9bb4-4772-aa40-564eec3ad195"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>SUNLENCA tablets: Each tablet contains 300 mg of lenacapavir (present as 306.8 mg of lenacapavir sodium). The tablets are beige, capsule-shaped, film-coated, and debossed with 'GSI' on one side of the tablet and '62L' on the other side of the tablet.</paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="c5913f4c-411e-48d5-aee8-24ac0fcc38ff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>SUNLENCA injection: Each single-dose vial contains 463.5 mg/1.5 mL (309 mg/mL) of lenacapavir (present as 473.1 mg/1.5 mL of lenacapavir sodium). The lenacapavir injectable solution is sterile, preservative-free, clear, and yellow with no visible particles.</paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="ced184f6-1c0a-45f2-aca5-e1f629cc3579"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Concomitant administration of SUNLENCA with strong CYP3A inducers is contraindicated due to decreased lenacapavir plasma concentrations, which may result in the loss of therapeutic effect and development of resistance to SUNLENCA <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content>.</paragraph>
               </text>
               <effectiveTime value="20241125"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Concomitant administration of SUNLENCA is contraindicated with strong CYP3A inducers. (<linkHtml href="#S4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="239cba54-3787-413e-b670-2259b3b0f73e"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20241125"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Immune reconstitution syndrome: May necessitate further evaluation and treatment. (<linkHtml href="#S2.1">5.1</linkHtml>)</item>
                           <item>Residual concentrations of lenacapavir may remain in systemic circulation for up to 12 months or longer. Counsel patients regarding the dosing schedule; non-adherence could lead to loss of virologic response and development of resistance. (<linkHtml href="#S5.2">5.2</linkHtml>)</item>
                           <item>May increase exposure and risk of adverse reactions to drugs primarily metabolized by CYP3A initiated within 9 months after the last subcutaneous dose of SUNLENCA. (<linkHtml href="#S5.2">5.2</linkHtml>)</item>
                           <item>If discontinued, initiate an alternative, fully suppressive antiretroviral regimen where possible no later than 28 weeks after the final injection of SUNLENCA. If virologic failure occurs, switch to an alternative regimen if possible. (<linkHtml href="#S5.2">5.2</linkHtml>)</item>
                           <item>Injection site reactions may occur, and nodules and indurations may be persistent. Improper administration (intradermal injection) has been associated with serious injection site reactions. (<linkHtml href="#S5.3">5.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="e9cd0b7d-7b26-45d6-9949-2757181f0fb3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Immune Reconstitution Syndrome</title>
                     <text>
                        <paragraph>Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections [such as <content styleCode="italics">Mycobacterium avium</content> infection, cytomegalovirus, <content styleCode="italics">Pneumocystis jirovecii</content> pneumonia (PCP), or tuberculosis], which may necessitate further evaluation and treatment.</paragraph>
                        <paragraph>Autoimmune disorders (such as Graves' disease, polymyositis, Guillain-Barré syndrome, and autoimmune hepatitis) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment.</paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="b47420ab-2090-40fb-af70-798a0a353d91"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2	Long-Acting Properties and Potential Associated Risks with SUNLENCA</title>
                     <text>
                        <paragraph>Residual concentrations of lenacapavir may remain in the systemic circulation of patients for prolonged periods (up to 12 months or longer after the last subcutaneous dose). It is important to counsel patients that maintenance dosing by injection is required every 6 months, because missed doses or non-adherence to injections could lead to loss of virologic response and development of resistance <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>Lenacapavir, a moderate CYP3A inhibitor, may increase the exposure to, and therefore potential risk of adverse reactions from, drugs primarily metabolized by CYP3A initiated within 9 months after the last subcutaneous dose of SUNLENCA <content styleCode="italics">[see <linkHtml href="#S7.2">Drug Interactions and Clinical Pharmacology (7.2</linkHtml>, <linkHtml href="#S12.3">12.3)</linkHtml>]</content>.</paragraph>
                        <paragraph>If SUNLENCA is discontinued, to minimize the potential risk of developing viral resistance, it is essential to initiate an alternative, fully suppressive antiretroviral regimen where possible no later than 28 weeks after the final injection of SUNLENCA. If virologic failure occurs during treatment, switch the patient to an alternative regimen if possible <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="1f9ec182-d906-471c-99ac-b43573e7772b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3	Injection Site Reactions</title>
                     <text>
                        <paragraph>Administration of SUNLENCA may result in local injection site reactions (ISRs). If clinically significant ISRs occur, evaluate and institute appropriate therapy and follow-up.</paragraph>
                        <paragraph>Manifestations of ISRs may include swelling, pain, erythema, nodule, induration, pruritus, extravasation or mass. Nodules and indurations at the injection site may take longer to resolve than other ISRs. In clinical studies, after a median follow-up of 553 days, 30% of nodules and 13% of indurations (in 10% and 1% of participants, respectively) associated with the first injections of SUNLENCA had not fully resolved. Measurements and qualitative assessments of ISRs were not routinely reported. Where described, the majority of the injection site nodules and indurations were palpable but not visible, and had a maximum size of approximately 1 to 4 cm <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>The mechanism driving the persistence of injection site nodules and indurations in some patients is not fully understood, but based on available data, they may be related to the presence of the subcutaneous drug depot. In some patients who had a skin biopsy performed of an injection site nodule or induration, dermatopathology revealed foreign body inflammation or granulomatous response.</paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Improper administration (intradermal injection) has been associated with serious injection site reactions, including necrosis and ulcer <content styleCode="italics">[see <linkHtml href="#S6">Adverse Reactions (6)</linkHtml>]</content>. Ensure SUNLENCA is only administered subcutaneously in the abdomen <content styleCode="italics">[see <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>]</content>.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="44fd7fea-c965-4e38-a309-9518b02cb81a"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions are discussed in other sections of the labeling:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Immune Reconstitution Syndrome <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>Injection Site Reactions <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>].</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20241125"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (incidence greater than or equal to 3%, all grades) are nausea and injection site reactions. (<linkHtml href="#S6.1">6.1</linkHtml>)</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Gilead Sciences, Inc. at 1-800-GILEAD-5 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="0e847dc4-0f49-41be-8756-1473a24080a6"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The primary safety assessment of SUNLENCA was based on data from heavily treatment-experienced adult participants with HIV who received SUNLENCA in a Phase 2/3 trial (CAPELLA; N=72) through Week 52 (median duration on study of 71 weeks) <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>, as well as supportive data in treatment-naïve adult participants with HIV who received SUNLENCA in a Phase 2 trial (CALIBRATE; N=157) through Week 54 (median duration of exposure of 66 weeks).</paragraph>
                        <paragraph>The most common adverse reactions (all Grades) reported in at least 3% of participants in CAPELLA were nausea and injection site reactions. The proportion of partcipants in CAPELLA who discontinued treatment with SUNLENCA due to adverse events, regardless of severity, was 1% (Grade 1 injection site nodule in 1 participant). Table 3 displays the frequency of adverse reactions (all Grades) greater than or equal to 3% in the SUNLENCA group.</paragraph>
                        <table width="75%" ID="table3a">
                           <caption>Table 3	Adverse Reactions (All Grades) Reported in ≥ 3% <footnote>Frequencies of adverse reactions are based on all adverse events attributed to trial drug by the investigator, based on all participants (cohorts 1 and 2) in CAPELLA.</footnote> of Heavily Treatment Experienced Adults with HIV-1 Receiving SUNLENCA  in CAPELLA (Week 52 Analysis)</caption>
                           <col width="70%" align="left" valign="middle"/>
                           <col width="30%" align="center" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule" valign="bottom">Adverse Reactions</th>
                                 <th styleCode="Rrule">SUNLENCA + Background Regimen<br/>(N=72)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Injection Site Reactions</td>
                                 <td styleCode="Rrule">65%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Nausea</td>
                                 <td styleCode="Rrule">4%</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The majority (96%) of all adverse reactions associated with SUNLENCA were mild or moderate in severity.</paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                     <component>
                        <section>
                           <id root="ad3d97cc-0c0d-41f1-a4d2-50231c3182f3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Injection-Associated Adverse Reactions</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241125"/>
                           <component>
                              <section>
                                 <id root="23c62abf-ef93-42ed-9ba0-305dcb9b6ada"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Local Injection Site Reactions (ISRs)</content>: </paragraph>
                                    <paragraph>The most frequent adverse reactions were ISRs. Of the 72 participants in CAPELLA, 65% had experienced an ISR attributed to study drug through at least the Week 52 visit. Most participants had mild (Grade 1, 44%) or moderate (Grade 2, 17%) ISRs. Four percent of participants experienced a severe (Grade 3) ISR (erythema, pain, swelling) that resolved within 15 days. The ISRs reported in more than 1% of participants were swelling (36%), pain (31%), erythema (31%), nodule (25%), induration (15%), pruritus (6%), extravasation (3%) and mass (3%). ISRs reported in 1% of participants included discomfort, hematoma, edema, and ulcer.</paragraph>
                                    <paragraph>Nodules and indurations at the injection site took longer to resolve than other ISRs. The median time to resolution of all ISRs, excluding nodules and indurations, was 5 days (range: 1 to 183). The median time to resolution of nodules and indurations associated with the first injections of SUNLENCA was 148 (range: 41 to 727) and 70 (range: 3 to 252) days, respectively. After a median follow up of 553 days, 30% of nodules and 13% of indurations (in 10% and 1% of participants, respectively) associated with the first injections of SUNLENCA had not fully resolved. Qualitative descriptions of injection site nodules and indurations were not routinely reported, but, where reported, the majority of injection site nodules and indurations were palpable but not visible. Measurements of injection site nodules and indurations were not routinely performed or standardized, but where measurements were reported, the maximum size for the majority of injection site nodules and indurations was approximately 1 to 4 cm <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20241125"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="64b6dadf-b264-44e8-8ee4-bb462f82a353"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Laboratory Abnormalities</content>
                              </paragraph>
                              <paragraph>The frequency of laboratory abnormalities (Grades 3 to 4) occurring in at least 2% of participants in CAPELLA are presented in Table 4. A causal association between SUNLENCA and these laboratory abnormalities has not been established.</paragraph>
                              <table width="60%" ID="table4">
                                 <caption>Table 4	Selected Laboratory Abnormalities (Grades 3 to 4) Reported in ≥ 2% of Participants Receiving SUNLENCA in CAPELLA (Week 52 Analysis)</caption>
                                 <col width="70%" align="left" valign="middle"/>
                                 <col width="30%" align="center" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule" valign="bottom">Laboratory Parameter Abnormality</th>
                                       <th styleCode="Rrule">SUNLENCA + Background Regimen <br/>(N=72) <footnote>Frequencies are based on treatment-emergent laboratory abnormalities in all participants (cohorts 1 and 2) in CAPELLA. Percentages were calculated based on the number of participants with post-baseline toxicity grades for each laboratory parameter (n=72 for all parameters except hyperglycemia fasting n=57).</footnote>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td align="left" valign="top" colspan="2">ALT= alanine aminotransferase; AST= aspartate aminotransferase; ULN = upper limit of normal</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Creatinine ( &gt;1.8 × ULN or ≥1.5 × baseline)</td>
                                       <td styleCode="Rrule">13%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Glycosuria (&gt;2+) <footnote ID="foot2">Grade 3 only (no Grade 4 values reported).</footnote>
                                       </td>
                                       <td styleCode="Rrule">6%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hyperglycemia (fasting) (&gt;250 mg/dL)</td>
                                       <td styleCode="Rrule">5%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Proteinuria (&gt;2+) <footnoteRef IDREF="foot2"/>
                                       </td>
                                       <td styleCode="Rrule">4%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">ALT (≥5 × ULN) <footnoteRef IDREF="foot2"/>
                                       </td>
                                       <td styleCode="Rrule">3%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">AST (≥5 × ULN)</td>
                                       <td styleCode="Rrule">3%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Direct Bilirubin (&gt;ULN) <footnoteRef IDREF="foot2"/>
                                       </td>
                                       <td styleCode="Rrule">3%</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20241125"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="b20020dc-94e6-4b24-82d4-f83a65297422"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>In addition to adverse reactions reported from clinical trials, the following adverse reactions have been identified during postmarketing use. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                     <component>
                        <section>
                           <id root="20696e3a-955d-4017-b5ca-d6f3b4c43ba5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">General disorders and administration site conditions</content>
                              </paragraph>
                              <paragraph>Injection site necrosis <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20241125"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="b5b64b74-92a0-498e-a940-e4c79be1b301"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20241125"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (<linkHtml href="#S4">4</linkHtml>, <linkHtml href="#S7">7</linkHtml>,  <linkHtml href="#S12.3">12.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="85b47db2-e22d-4d33-ae43-69ff71802309"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1	Effect of Other Drugs on SUNLENCA</title>
                     <text>
                        <paragraph>Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A.</paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                     <component>
                        <section>
                           <id root="5fad96e3-2697-48a7-ac33-32036bc80d11"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Strong or Moderate CYP3A Inducers</content>
                              </paragraph>
                              <paragraph>Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>, which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>. Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended.</paragraph>
                           </text>
                           <effectiveTime value="20241125"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="8788dbe2-a319-4c40-a60b-ddc0773c9cc6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors</content>
                              </paragraph>
                              <paragraph>Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommended.</paragraph>
                           </text>
                           <effectiveTime value="20241125"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="c66aaa77-96d7-48b4-95ab-1178af54aba6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2	Effect of SUNLENCA on Other Drugs</title>
                     <text>
                        <paragraph>Lenacapavir is a moderate inhibitor of CYP3A. Due to the long half-life of lenacapavir following subcutaneous administration, SUNLENCA may increase the exposure of  drugs primarily metabolized by CYP3A <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content> initiated within 9 months after the last subcutaneous dose of SUNLENCA, which may increase the potential risk of adverse reactions. See the prescribing information of the sensitive CYP3A substrate for dosing recommendations with moderate inhibitors of CYP3A.</paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.3">
                     <id root="f0f57980-f97b-4ff0-a487-b911d510f6bd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3	Established and Other Potentially Significant Drug Interactions </title>
                     <text>
                        <paragraph>Table 5 provides a listing of clinically significant drug interactions with recommended prevention or management strategies, but is not all inclusive. The drug interactions described are based on studies conducted with SUNLENCA or are drug interactions that may occur with SUNLENCA <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml> and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                        <table width="90%" ID="table5">
                           <caption>Table 5		Drug Interactions with SUNLENCA</caption>
                           <col width="35%" align="left" valign="top"/>
                           <col width="25%" align="center" valign="top"/>
                           <col width="40%" align="left" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule" valign="bottom">Concomitant Drug Class: <br/>Drug Name</th>
                                 <th styleCode="Rrule" valign="bottom">Effect on Concentration <footnote ID="foot5b">↑ = Increase, ↓ = Decrease.</footnote>
                                 </th>
                                 <th styleCode="Rrule" align="center" valign="bottom">Clinical Comment</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Antiarrhythmics:</content>
                                    <br/>digoxin</td>
                                 <td styleCode="Rrule">↑ digoxin</td>
                                 <td styleCode="Rrule">Use with caution and monitor digoxin therapeutic concentration.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Anticoagulants:</content>
                                    <br/>Direct Oral Anticoagulants (DOACs)<br/>  rivaroxaban<br/>  dabigatran<br/>  edoxaban</td>
                                 <td styleCode="Rrule">↑ DOAC</td>
                                 <td styleCode="Rrule">Refer to the DOAC prescribing information for concomitant administration with  moderate CYP3A inhibitors and/or P-gp inhibitors.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Anticonvulsants:</content>
                                    <br/>carbamazepine<br/>oxcarbazepine<br/>phenobarbital<br/>phenytoin</td>
                                 <td styleCode="Rrule">↓ lenacapavir</td>
                                 <td styleCode="Rrule">Concomitant administration of carbamazepine, oxcarbazepine, phenobarbital, or phenytoin may result in loss of therapeutic effect and development of resistance.<br/> Concomitant administration of SUNLENCA with carbamazepine or phenytoin is contraindicated.<br/>Concomitant administration of SUNLENCA with oxcarbazepine or phenobarbital is not recommended. Consider use of alternative anticonvulsants.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Antiretroviral Agents:</content>
                                    <br/>atazanavir/cobicistat <footnote ID="foot5c">Drug-drug interaction study was conducted.</footnote>
                                    <br/>atazanavir/ritonavir</td>
                                 <td styleCode="Rrule">↑ lenacapavir (atazanavir/cobicistat, atazanavir/ritonavir)</td>
                                 <td styleCode="Rrule" align="left">Concomitant administration of efavirenz, nevirapine, or tipranavir/ritonavir may result in loss of therapeutic effect and development of resistance.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule">efavirenz <footnoteRef IDREF="foot5c"/>
                                    <br/>nevirapine<br/>tipranavir/ritonavir</td>
                                 <td styleCode="Botrule Rrule" align="center">↓ lenacapavir (efavirenz, nevirapine, tipranavir/ritonavir)</td>
                                 <td styleCode="Botrule Rrule" align="left">Concomitant administration with atazanavir/cobicistat, atazanavir/ritonavir, efavirenz, nevirapine, or tipranavir/ritonavir is not recommended.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Antimycobacterials:</content>
                                    <br/>rifabutin<br/>rifampin <footnoteRef IDREF="foot5c"/>
                                    <br/>rifapentine</td>
                                 <td styleCode="Rrule">↓ lenacapavir</td>
                                 <td styleCode="Rrule">Concomitant administration of rifabutin, rifampin and rifapentine may result in loss of therapeutic effect and development of resistance.<br/>Concomitant administration of SUNLENCA with rifampin is contraindicated <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.<br/>Concomitant administration of SUNLENCA with rifabutin or rifapentine is not recommended.  </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Corticosteroids (systemic):</content>
                                    <br/>cortisone/hydrocortisone<br/>dexamethasone</td>
                                 <td styleCode="Rrule">↑ corticosteroids (systemic)</td>
                                 <td styleCode="Rrule">Concomitant administration with systemic corticosteroids whose exposures are significantly increased by CYP3A inhibitors can increase the risk for Cushing's syndrome and adrenal suppression. Initiate with the lowest starting dose and titrate carefully while monitoring for safety.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule"/>
                                 <td styleCode="Rrule">↓ lenacapavir (dexamethasone)</td>
                                 <td styleCode="Rrule">Concomitant administration of systemic dexamethasone may result in loss of therapeutic effect of lenacapavir and development of resistance. Alternative corticosteroids to dexamethasone should be considered, particularly for long-term use.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Ergot derivatives:</content>
                                    <br/>dihydroergotamine<br/>ergotamine<br/>methylergonovine</td>
                                 <td styleCode="Rrule">↑ dihydroergotamine<br/>↑ ergotamine<br/>↑ methylergonovine</td>
                                 <td styleCode="Rrule">Concomitant administration of SUNLENCA with dihydroergotamine, ergotamine or methylergonovine is not recommended.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Herbal Products:</content>
                                    <br/>St. John's wort <footnote>The induction potency of St. John's wort may vary widely based on preparation.</footnote>
                                    <br/>
                                    <content styleCode="italics">(Hypericum perforatum)</content>
                                 </td>
                                 <td styleCode="Rrule">↓ lenacapavir</td>
                                 <td styleCode="Rrule">Concomitant administration of St. John's wort may result in loss of therapeutic effect and development of resistance. <br/>Concomitant administration of SUNLENCA with St. John's wort is contraindicated.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">HMG-CoA Reductase Inhibitors:</content>
                                    <br/>lovastatin<br/>simvastatin</td>
                                 <td styleCode="Rrule">↑ lovastatin<br/>↑ simvastatin</td>
                                 <td styleCode="Rrule">Initiate lovastatin and simvastatin with the lowest starting dose and titrate carefully while monitoring for safety (e.g., myopathy).</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Narcotic analgesics metabolized by CYP3A:</content>
                                    <br/>e.g., fentanyl, oxycodone</td>
                                 <td styleCode="Rrule">↑ fentanyl<br/>↑ oxycodone</td>
                                 <td styleCode="Rrule">Careful monitoring of therapeutic effects and adverse reactions associated with CYP3A-metabolized narcotic analgesics (including potentially fatal respiratory depression) is recommended with co-administration.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">tramadol</td>
                                 <td styleCode="Rrule">↑ tramadol</td>
                                 <td styleCode="Rrule">A decrease in dose may be needed for tramadol with concomitant use.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Narcotic analgesic for treatment of opioid dependence:</content>
                                    <br/>buprenorphine, methadone</td>
                                 <td styleCode="Rrule">buprenorphine: effects unknown<br/>methadone: effects unknown</td>
                                 <td styleCode="Rrule">Initiation of buprenorphine or methadone in patients taking SUNLENCA: Carefully titrate the dose of buprenorphine or methadone to the desired effect; use the lowest feasible initial or maintenance dose.<br/>Initiation of SUNLENCA in patients taking buprenorphine or methadone: A dose adjustment for buprenorphine or methadone may be needed. Monitor clinical signs and symptoms.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Opioid Antagonist:</content>
                                    <br/>naloxegol</td>
                                 <td styleCode="Rrule">↑ naloxegol</td>
                                 <td styleCode="Rrule">Avoid use with SUNLENCA; if unavoidable, decrease the dosage of naloxegol and monitor for adverse reactions.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Phosphodiesterase-5 (PDE-5) Inhibitors:</content>
                                    <br/>sildenafil<br/>tadalafil<br/>vardenafil</td>
                                 <td styleCode="Rrule">↑ PDE-5 inhibitors</td>
                                 <td styleCode="Rrule">Use of PDE-5 inhibitors for pulmonary arterial hypertension (PAH): <br/>Concomitant administration of SUNLENCA with tadalafil for the treatment of PAH is not recommended.<br/>Use of PDE-5 inhibitors for erectile dysfunction (ED):<br/>Refer to the prescribing information of PDE-5 inhibitors for dose recommendations.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Sedatives/Hypnotics:</content>
                                    <br/>midazolam (oral) <footnoteRef IDREF="foot5c"/>
                                    <br/>triazolam</td>
                                 <td styleCode="Rrule">↑ midazolam (oral)<br/>↑ triazolam</td>
                                 <td styleCode="Rrule">Use with caution when midazolam or triazolam is concomitantly administered with SUNLENCA</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.4">
                     <id root="b2f9fc14-ea70-4a39-a5d9-b88c808464fc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.4	Drugs without Clinically Significant Interactions with SUNLENCA</title>
                     <text>
                        <paragraph>Based on drug interaction studies conducted with SUNLENCA, no clinically significant drug interactions have been observed with: darunavir/cobicistat, cobicistat, famotidine, pitavastatin, rosuvastatin, tenofovir alafenamide, and voriconazole.</paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="0111b150-5292-4abc-b5e8-22c0fafddd99"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20241125"/>
               <component>
                  <section ID="S8.1">
                     <id root="25d3be42-9eb7-4d7a-8676-0cb8ec36c99b"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20241125"/>
                     <component>
                        <section>
                           <id root="08740304-9841-4856-8470-e42a7d40cbc3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pregnancy Exposure Registry</content>
                              </paragraph>
                              <paragraph>There is a pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to SUNLENCA during pregnancy. Healthcare providers are encouraged to register patients by calling the Antiretroviral Pregnancy Registry (APR) at 1-800-258-4263.</paragraph>
                           </text>
                           <effectiveTime value="20241125"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="a94abb01-94d0-44d2-b512-3c44c8606b9e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are insufficient human data on the use of SUNLENCA during pregnancy to inform a drug-associated risk of birth defects and miscarriage. In animal reproduction studies, no adverse developmental effects were observed when lenacapavir was administered to rats and rabbits at exposures (AUC) ≥16 times the exposure in humans at the recommended human dose (RHD) of SUNLENCA (<content styleCode="italics">see <linkHtml href="#data">Data</linkHtml>
                                 </content>).</paragraph>
                              <paragraph>The background risk of major birth defects and miscarriage for the indicated population is unknown. The background rate of major birth defects in a U.S. reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP) is 2.7%. The rate of miscarriage is not reported in the APR. The estimated background rate of miscarriage in clinically recognized pregnancies in the U.S. general population is 15 to 20%.</paragraph>
                           </text>
                           <effectiveTime value="20241125"/>
                        </section>
                     </component>
                     <component>
                        <section ID="data">
                           <id root="02ca14a2-950a-44ba-9e1a-b293306da2b1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241125"/>
                           <component>
                              <section>
                                 <id root="a3d6bc54-012b-4c2c-a6b4-fec474783522"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>Lenacapavir was administered intravenously to pregnant rabbits (up to 20 mg/kg/day on gestation days (GD) 7 to 19), orally to rats (up to 300 mg/kg/day on GD 6 to 17), and subcutaneously to rats (up to 300 mg/kg on GD 6). No significant toxicological effects on embryo-fetal (rats and rabbits) or pre/postnatal (rats) development were observed at exposures (AUC) approximately 16 times (rats) and 39 times (rabbits) the exposure in humans at the RHD of SUNLENCA.</paragraph>
                                 </text>
                                 <effectiveTime value="20241125"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="5b49bdf4-8f9d-4105-ba59-ca8257585c3b"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20241125"/>
                     <component>
                        <section>
                           <id root="72d51e9e-e783-49b2-84cd-e9d37dc6c1de"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>It is not known whether SUNLENCA is present in human breast milk, affects human milk production, or has effects on the breastfed infant. After administration to pregnant rats, lenacapavir was detected in the plasma of nursing rat pups, without effects on these nursing pups <content styleCode="italics">(see <linkHtml href="#data2">Data</linkHtml>)</content>. </paragraph>
                              <paragraph>Potential risks of breastfeeding include: (1) HIV-1 transmission (in infants without HIV-1), (2) developing viral resistance (in infants with HIV-1), and (3) adverse reactions in a breastfed infant similar to those seen in adults.</paragraph>
                           </text>
                           <effectiveTime value="20241125"/>
                        </section>
                     </component>
                     <component>
                        <section ID="data2">
                           <id root="66cdc181-f24f-4d85-a8f6-f700b495a7b8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                              <paragraph>Lenacapavir was detected at low levels in the plasma of nursing rat pups in the pre/postnatal development study (post-natal day 10).</paragraph>
                           </text>
                           <effectiveTime value="20241125"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="1b54e705-cb87-42f8-86ba-92ca959b45fc"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of SUNLENCA have not been established in pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="8417df4a-a3fd-4964-824f-125729cda0ad"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of SUNLENCA did not include sufficient numbers of participants aged 65 and over to determine whether they respond differently from younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="94415d07-55bd-4a80-9bd0-d2fa7259b57e"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>No dosage adjustment of SUNLENCA is recommended in patients with mild, moderate or severe renal impairment (estimated creatinine clearance greater than or equal to 15 mL per minute)<content styleCode="italics">.</content> SUNLENCA has not been studied in patients with ESRD (estimated creatinine clearance less than 15 mL per minute) <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.7">
                     <id root="a55a061a-8a2b-46b2-af2b-1208429e4de0"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.7 Hepatic Impairment</title>
                     <text>
                        <paragraph>No dosage adjustment of SUNLENCA is recommended in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment<content styleCode="italics">.</content> SUNLENCA has not been studied in patients with severe hepatic impairment (Child-Pugh Class C) <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="e88cc4be-8981-4324-b27b-ceb8a74fcb01"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>No data are available on overdose of SUNLENCA in patients. If overdose occurs, monitor the patient for evidence of toxicity. Treatment of overdose with SUNLENCA consists of general supportive measures including monitoring of vital signs as well as observation of the clinical status of the patient. As lenacapavir is highly bound to plasma proteins, it is unlikely to be significantly removed by dialysis. </paragraph>
               </text>
               <effectiveTime value="20241125"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="981514a1-07c9-485f-a1a2-05bb545fc575"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>SUNLENCA tablets and SUNLENCA injection contain lenacapavir sodium, a capsid inhibitor.</paragraph>
                  <paragraph>The chemical name of lenacapavir sodium is: Sodium (4-chloro-7-(2-((<content styleCode="italics">S</content>)-1-(2-((3b<content styleCode="italics">S</content>,4a<content styleCode="italics">R</content>)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1<content styleCode="italics">H</content>-cyclopropa[3,4]cyclopenta[1,2-<content styleCode="italics">c</content>]pyrazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)pyridin-3-yl)-1-(2,2,2-trifluoroethyl)-1<content styleCode="italics">H</content>-indazol-3-yl)(methylsulfonyl)amide.</paragraph>
                  <paragraph>Lenacapavir sodium has a molecular formula of C<sub>39</sub>H<sub>31</sub>ClF<sub>10</sub>N<sub>7</sub>NaO<sub>5</sub>S<sub>2,</sub> a molecular weight of 990.3, and the following structural formula:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM5"/>
                  </paragraph>
                  <paragraph>Lenacapavir sodium is a light yellow to yellow solid and is practically insoluble in water.</paragraph>
               </text>
               <effectiveTime value="20241125"/>
               <component>
                  <observationMedia ID="MM5">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="sunlenca-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <section>
                     <id root="b274a824-c6ad-44dc-8ecb-c54a5e17b883"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">SUNLENCA tablets</content> are for oral administration. Each film-coated tablet contains 300 mg of lenacapavir (present as 306.8 mg lenacapavir sodium) and the following inactive ingredients: copovidone, croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, and poloxamer 407. The tablets are film-coated with a coating material containing iron oxide black, iron oxide red, iron oxide yellow, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide. </paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="26780d77-5856-45d8-8378-2490ab429446"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">SUNLENCA injection</content> is for subcutaneous administration. Each single-dose vial contains 463.5 mg/1.5 mL (309 mg/mL) of lenacapavir (present as 473.1 mg/1.5 mL of lenacapavir sodium) as a sterile, preservative-free, clear, yellow solution and the following inactive ingredients: 896.3 mg of polyethylene glycol 300 (as solvent) and water for injection. The apparent pH range of the injection is 9.0–10.2.</paragraph>
                        <paragraph>The vial stoppers are not made with natural rubber latex.</paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="6103718e-d56f-464f-88c5-67a5d5d6d055"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20241125"/>
               <component>
                  <section ID="S12.1">
                     <id root="ce71abeb-d73d-47d4-b6cd-6fe35fafc325"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>SUNLENCA is an HIV-1 antiretroviral agent <content styleCode="italics">[see <linkHtml href="#S12.4">Microbiology (12.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="a149744e-bbec-4976-9a34-00ba0bfe02b8"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <effectiveTime value="20241125"/>
                     <component>
                        <section>
                           <id root="976f1742-7008-4a83-9e6c-4b1ef298f539"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Exposure-Response</content>
                              </paragraph>
                              <paragraph>In CAPELLA, oral loading doses (600 mg on Day 1 and Day 2, 300 mg on Day 8) followed by subcutaneous doses (927 mg every 6 months starting on Day 15) of SUNLENCA in heavily treatment-experienced participants with multiclass resistant HIV-1, efficacy outcomes (change in plasma HIV-1 RNA from Day 1 to Day 14, and percentage of participants with HIV-1 RNA less than 50 copies/mL at Week 26) were similar across the range of observed lenacapavir exposures.</paragraph>
                           </text>
                           <effectiveTime value="20241125"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="99c94453-5086-45fa-9005-ae0bb8776542"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cardiac Electrophysiology</content>
                              </paragraph>
                              <paragraph>At supratherapeutic exposures of lenacapavir (9-fold higher than the therapeutic exposures of SUNLENCA), SUNLENCA does not prolong the QTcF interval to any clinically relevant extent.</paragraph>
                           </text>
                           <effectiveTime value="20241125"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="da8a009b-0dca-435b-8e83-a21333782882"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The pharmacokinetic (PK) properties of lenacapavir are provided in Table 6 and Table 7. The estimated lenacapavir exposures are comparable between the two recommended dosing regimens.</paragraph>
                        <table width="65%" ID="table6">
                           <caption>Table 6	Pharmacokinetic Properties of Lenacapavir</caption>
                           <col width="24%" align="left" valign="top"/>
                           <col width="10%" align="center" valign="top"/>
                           <col width="33%" align="center" valign="top"/>
                           <col width="33%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule" colspan="2"/>
                                 <th styleCode="Rrule">Oral</th>
                                 <th styleCode="Rrule">Subcutaneous</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="4">
                                    <content styleCode="bold">Absorption</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">% Absolute bioavailability</td>
                                 <td styleCode="Rrule">6 to 10</td>
                                 <td styleCode="Rrule">100 <footnote ID="foot6a">Values reflect absolute bioavailability following subcutaneous administration of the 927 mg dose.</footnote>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">T<sub>max</sub> <footnote ID="foot6b">Values reflect administration of lenacapavir with or without food.</footnote>
                                 </td>
                                 <td styleCode="Rrule">4 hours</td>
                                 <td styleCode="Rrule">77 to 84 days <footnote ID="foot6c">Due to slow release from the site of subcutaneous administration, the absorption profile of subcutaneously administered lenacapavir is complex.</footnote>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="4">
                                    <content styleCode="bold">Effect of Food</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="2">Effect of low-fat meal (relative to fasting) <footnote ID="foot6d">Values refer to geometric mean ratio [low-fat meal/fasting] in PK parameters and (90% confidence interval). Low fat meal is approximately 400 kcal, 25% fat.</footnote>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="left">AUC<sub>inf </sub> ratio</td>
                                 <td styleCode="Botrule Rrule">98.6 (58.2,167.2)</td>
                                 <td styleCode="Botrule Rrule" valign="middle">-</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">C<sub>max</sub> ratio</td>
                                 <td styleCode="Rrule" align="center">115.8 (55.4, 242.1)</td>
                                 <td styleCode="Rrule" valign="middle">-</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="2">Effect of high-fat meal (relative to fasting) <footnote ID="foot6e">Values refer to geometric mean ratio [high-fat meal/fasting] in PK parameters and (90% confidence interval). High fat meal is approximately 1000 kcal, 50% fat.</footnote>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="left">AUC<sub>inf</sub> ratio</td>
                                 <td styleCode="Botrule Rrule" valign="middle">115.2 (72.0, 184.5)</td>
                                 <td styleCode="Botrule Rrule" valign="middle">-</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">C<sub>max</sub> ratio</td>
                                 <td styleCode="Rrule" align="center">145.2 (77.9, 270.5)</td>
                                 <td styleCode="Rrule" valign="middle">-</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="4">
                                    <content styleCode="bold">Distribution</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">Apparent volume of distribution (Vd/F, L)</td>
                                 <td styleCode="Rrule" valign="middle">19240</td>
                                 <td styleCode="Rrule" valign="middle">9500 to 11700</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">% bound to human plasma proteins</td>
                                 <td styleCode="Rrule" colspan="2" valign="bottom">&gt;98.5</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">Blood-to-plasma ratio</td>
                                 <td styleCode="Rrule" colspan="2">0.5 to 0.7 <footnote ID="foot6f">Values reflect the blood-to-plasma ratio of lenacapavir following a single dose intravenous administration of [<sup>14</sup>C] lenacapavir through 336 hours postdose.</footnote>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="4">
                                    <content styleCode="bold">Elimination</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">t<sub>1/2</sub>
                                 </td>
                                 <td styleCode="Rrule">10 to 12 days</td>
                                 <td styleCode="Rrule">8 to 12 weeks</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">Clearance (mean apparent clearance, L/h)</td>
                                 <td styleCode="Rrule" valign="middle">55</td>
                                 <td styleCode="Rrule" valign="middle">4.2</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">% of dose of unchanged drug in plasma <footnote ID="foot6g">Dosing in mass balance studies: single dose intravenous administration of [<sup>14</sup>C] lenacapair to participants without HIV-1.</footnote>
                                 </td>
                                 <td styleCode="Rrule" colspan="2" valign="middle">69</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="4">
                                    <content styleCode="bold">Metabolism</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">Metabolic pathway(s)</td>
                                 <td styleCode="Rrule" colspan="2">CYP3A (minor)<br/>UGT1A1 (minor)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="4">
                                    <content styleCode="bold">Excretion</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">Major routes of elimination</td>
                                 <td styleCode="Rrule" colspan="2">Excretion of unchanged drug into feces <footnote ID="foot6h">Metabolized via oxidation, N-dealkylation, hydrogenation, amide hydrolysis, glucuronidation, hexose conjugation, pentose conjugation, and glutathione conjugation; primarily via CYP3A and UGT1A1 and no single circulating metabolite accounted for &gt;10% of plasma drug-related exposure.</footnote>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">% of dose excreted in urine <footnoteRef IDREF="foot6g"/>
                                 </td>
                                 <td styleCode="Rrule" colspan="2" valign="middle">&lt;1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" colspan="2">% of dose excreted in feces (% unchanged) <footnoteRef IDREF="foot6h"/>
                                 </td>
                                 <td styleCode="Rrule" colspan="2" valign="middle">76 (33)</td>
                              </tr>
                           </tbody>
                        </table>
                        <table width="90%" ID="table7">
                           <caption>Table 7	Lenacapavir Exposures Following Oral and Subcutaneous Administration of SUNLENCA in Heavily Treatment Experienced Participants with HIV</caption>
                           <col width="16%" align="left" valign="middle"/>
                           <col width="40%" align="center" valign="middle"/>
                           <col width="22%" align="center" valign="middle"/>
                           <col width="22%" align="center" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule" rowspan="3" valign="bottom">Parameter Mean (%CV)</th>
                                 <th styleCode="Rrule Botrule">Recommended Dosing Regimen, Option 1 <footnote ID="t7ft1">Predicted exposures utilizing population PK analysis.</footnote>
                                 </th>
                                 <th styleCode="Rrule Botrule" colspan="2">Recommended Dosing Regimen, Option 2 <footnoteRef IDREF="t7ft1"/>
                                 </th>
                              </tr>
                              <tr>
                                 <th styleCode="Rrule Botrule" align="center" valign="top">Day 1: 600 mg (oral) + 927 mg (SC)<br/>Day 2: 600 mg (oral)</th>
                                 <th styleCode="Rrule Botrule" colspan="2" valign="top">Days 1 and 2: 600 mg (oral), <br/>Day 8: 300 mg (oral),<br/>Day 15: 927 mg (SC)</th>
                              </tr>
                              <tr>
                                 <th styleCode="Rrule" valign="bottom" align="center">Day 1 to end of Month 6</th>
                                 <th styleCode="Rrule" valign="bottom">Days 1 to 15</th>
                                 <th styleCode="Rrule">Day 15 to end of Month 6</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="4" align="left">CV = coefficient of variation; NA = not applicable; SC = subcutaneous</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">C<sub>max</sub>
                                    <br/>(ng/mL) </td>
                                 <td styleCode="Rrule">101.4 (53.1)</td>
                                 <td styleCode="Rrule">88.0 (72.4)</td>
                                 <td styleCode="Rrule">86.5 (51.7)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">AUC<sub>tau</sub>
                                    <br/>(h∙ng/mL)</td>
                                 <td styleCode="Rrule">242266 (46.0)</td>
                                 <td styleCode="Rrule">19496 (72.6)</td>
                                 <td styleCode="Rrule">239163 (47.2)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">C<sub>trough</sub>
                                    <br/>(ng/mL)</td>
                                 <td styleCode="Rrule">32.5 (57.2)</td>
                                 <td styleCode="Rrule">46.9 (72.3)</td>
                                 <td styleCode="Rrule">32.5 (57.5)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Lenacapavir exposures after subcutaneous administration were similar between heavily treatment experienced participants with HIV-1 and participants without HIV-1 based on population pharmacokinetics analysis. Lenacapavir exposures (AUC<sub>tau</sub>, C<sub>max</sub> and C<sub>trough</sub>) after oral administration were 28% to 43% higher in participants with HIV-1 who were heavily treatment experienced, compared to participants without HIV-1 based on population PK analysis. These differences were not considered clinically relevant.</paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                     <component>
                        <section>
                           <id root="f6301af2-a321-4425-b3c0-103939bd2dfb"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                              <paragraph>There were no clinically significant differences in the pharmacokinetics of lenacapavir based on age (18 to 78 years), sex, ethnicity (hispanic or non-hispanic), race (white, black, asian or other), body weight (41.4 to 164 kg), severe renal impairment (creatinine clearance of 15 to less than 30 mL per minute, estimated by Cockroft-Gault method), or moderate hepatic impairment (Child-Pugh Class B). The effect of end-stage renal disease (including dialysis), or severe hepatic impairment (Child-Pugh Class C), on the pharmacokinetics of lenacapavir is unknown. As lenacapavir is greater than 98.5% protein bound, dialysis is not expected to alter exposures of lenacapavir <content styleCode="italics">[see <linkHtml href="#S8.6">Use in Specific Populations (8.6)</linkHtml>].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241125"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3e2c443c-bc4f-4e83-ac30-2ad7b9af7e60"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241125"/>
                           <component>
                              <section>
                                 <id root="446c440a-d45a-46bd-a689-fa1d2474c37c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline italics">Clinical Studies</content>
                                    </paragraph>
                                    <paragraph>Clinical drug-drug interaction study indicated that lenacapavir is a substrate of CYP3A, P-gp, and UGT1A1. Table 8 summarizes the pharmacokinetic effects of other drugs on lenacapavir. </paragraph>
                                    <paragraph>Lenacapavir is a moderate inhibitor of CYP3A. Lenacapavir is an inhibitor of P-gp and BCRP but does not inhibit OATP. Table 9 summarizes the pharmacokinetic effects of lenacapavir on other drugs.</paragraph>
                                    <table width="75%" ID="table8">
                                       <caption>Table 8	Effect of Other Drugs on Lenacapavir <footnote>Single dose of lenacapavir 300 mg administered orally.</footnote>
                                          <sup>,</sup>
                                          <footnote>All interaction studies conducted in participants without HIV-1.</footnote>
                                       </caption>
                                       <col width="36%" align="left" valign="middle"/>
                                       <col width="24%" align="center" valign="middle"/>
                                       <col width="20%" align="center" valign="middle"/>
                                       <col width="20%" align="center" valign="middle"/>
                                       <thead>
                                          <tr>
                                             <th styleCode="Lrule Rrule" rowspan="2" valign="bottom">Coadministered Drug</th>
                                             <th styleCode="Rrule" rowspan="2" valign="bottom">Dose of Coadministered Drug (mg)</th>
                                             <th styleCode="Botrule Rrule" colspan="2">Mean Ratio of Lenacapavir Pharmacokinetic Parameters (90% CI); No effect = 1.00</th>
                                          </tr>
                                          <tr>
                                             <th styleCode="Rrule" align="center">C<sub>max</sub>
                                             </th>
                                             <th styleCode="Rrule"> AUC</th>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Cobicistat (fed)<br/>(Inhibitor of CYP3A [strong] and P-gp)</td>
                                             <td styleCode="Rrule">150 once daily</td>
                                             <td styleCode="Rrule">2.10<br/>(1.62, 2.72)</td>
                                             <td styleCode="Rrule">2.28<br/>(1.75, 2.96)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Darunavir / cobicistat (fed)<br/>(Inhibitor of CYP3A [strong] and inhibitor and inducer of P-gp)</td>
                                             <td styleCode="Rrule">800/150 once daily</td>
                                             <td styleCode="Rrule">2.30<br/>(1.79, 2.95)</td>
                                             <td styleCode="Rrule">1.94<br/>(1.50, 2.52)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Voriconazole (fasted)<br/>(Inhibitor of CYP3A [strong])</td>
                                             <td styleCode="Rrule">400 twice daily, 200 twice daily <footnote>400 mg loading dose twice daily for a day, followed by 200 mg maintenance dose twice daily.</footnote>
                                             </td>
                                             <td styleCode="Rrule">1.09<br/>(0.81, 1.47)</td>
                                             <td styleCode="Rrule">1.41<br/>(1.10, 1.81)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Atazanavir / cobicistat (fed)<br/>(Inhibitor of CYP3A [strong] and UGT1A1 and P-gp)</td>
                                             <td styleCode="Rrule">300/150 once daily</td>
                                             <td styleCode="Rrule">6.60<br/>(4.99, 8.73)</td>
                                             <td styleCode="Rrule">4.21<br/>(3.19, 5.57)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Rifampin (fasted)<br/>(Inducer of CYP3A [strong] and P-gp and UGT)</td>
                                             <td styleCode="Rrule">600 once daily</td>
                                             <td styleCode="Rrule">0.45<br/>(0.34, 0.60)</td>
                                             <td styleCode="Rrule">0.16<br/>(0.12, 0.20)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Efavirenz (fasted)<br/>(Inducer of CYP3A [moderate] and P-gp)</td>
                                             <td styleCode="Rrule">600 once daily</td>
                                             <td styleCode="Rrule">0.64<br/>(0.45, 0.92)</td>
                                             <td styleCode="Rrule">0.44<br/>(0.32, 0.59)</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">Famotidine (2 hours before, fasted)</td>
                                             <td styleCode="Rrule">40 once daily</td>
                                             <td styleCode="Rrule">1.01<br/>(0.75, 1.34)</td>
                                             <td styleCode="Rrule">1.28<br/>(1.00, 1.63)</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <table width="75%" ID="table9">
                                       <caption>Table 9	Effect of Lenacapavir on Other Drugs <footnote>All interaction studies conducted in participants without HIV-1.</footnote>
                                          <sup>,</sup>
                                          <footnote>Following 600 mg twice daily for 2 days, single 600 mg doses of lenacapavir were administered with each coadministered drug, resulting in lenacapavir exposures similar to or higher than those at the recommended dosage regimen.</footnote>
                                       </caption>
                                       <col width="36%" align="left" valign="middle"/>
                                       <col width="24%" align="center" valign="middle"/>
                                       <col width="20%" align="center" valign="middle"/>
                                       <col width="20%" align="center" valign="middle"/>
                                       <thead>
                                          <tr>
                                             <th styleCode="Lrule Rrule" rowspan="2" valign="bottom" align="center">Coadministered Drug</th>
                                             <th styleCode="Rrule" rowspan="2" valign="bottom">Dose of Coadministered Drug (mg)</th>
                                             <th styleCode="Botrule Rrule" colspan="2">Mean Ratio of Coadministered Drug Pharmacokinetic Parameters (90% CI) <footnote>All No Effect Boundaries are 70% to 143%.</footnote>; No effect = 1.00</th>
                                          </tr>
                                          <tr>
                                             <th styleCode="Rrule" align="center">C<sub>max</sub>
                                             </th>
                                             <th styleCode="Rrule"> AUC</th>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule">Tenofovir alafenamide (fed)<br/>(substrate of P-gp)</td>
                                             <td styleCode="Rrule" valign="bottom">25 single dose</td>
                                             <td styleCode="Botrule Rrule">1.24<br/>(0.98, 1.58)</td>
                                             <td styleCode="Botrule Rrule">1.32<br/>(1.09, 1.59) </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Tenofovir <footnote>Tenofovir alafenamide is converted to tenofovir <content styleCode="italics">in vivo.</content>
                                                </footnote>
                                                <br/>(substrate of P-gp)</td>
                                             <td styleCode="Rrule"/>
                                             <td styleCode="Rrule">1.23<br/>(1.05, 1.44)</td>
                                             <td styleCode="Rrule">1.47<br/>(1.27, 1.71)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Pitavastatin (simultaneous administration, fed)<br/>(substrate of OATP)</td>
                                             <td styleCode="Rrule">2 single dose</td>
                                             <td styleCode="Rrule"> 1.00<br/>(0.84, 1.19)</td>
                                             <td styleCode="Rrule">1.11<br/>(1.00, 1.25)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Pitavastatin (3 days after lenacapavir, fed)<br/>(substrate of OATP)</td>
                                             <td styleCode="Rrule">2 single dose</td>
                                             <td styleCode="Rrule">0.85<br/>(0.69, 1.05)</td>
                                             <td styleCode="Rrule">0.96<br/>(0.87, 1.07)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Rosuvastatin (fed)<br/>(substrate of BCRP and OATP)</td>
                                             <td styleCode="Rrule">5 single dose</td>
                                             <td styleCode="Rrule">1.57<br/>(1.38, 1.80)</td>
                                             <td styleCode="Rrule">1.31<br/>(1.19, 1.43)</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule">Midazolam (simultaneous administration, fed)<br/>(substrate of CYP3A)</td>
                                             <td styleCode="Rrule">2.5 single dose</td>
                                             <td styleCode="Botrule Rrule">1.94<br/>(1.81, 2.08)</td>
                                             <td styleCode="Botrule Rrule">3.59<br/>(3.30, 3.91)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">1-hydroxymidazolam <footnote ID="t9fe">Major active metabolite of midazolam.</footnote>
                                                <br/>(substrate of CYP3A)</td>
                                             <td styleCode="Rrule"/>
                                             <td styleCode="Rrule">0.54<br/>(0.50, 0.59)</td>
                                             <td styleCode="Rrule">0.76<br/>(0.72, 0.80)</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule">Midazolam (1 day after lenacapavir, fed)<br/>(substrate of CYP3A)</td>
                                             <td styleCode="Rrule">2.5 single dose</td>
                                             <td styleCode="Botrule Rrule">2.16<br/>(2.02, 2.30)</td>
                                             <td styleCode="Botrule Rrule">4.08<br/>(3.77, 4.41)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">1-hydroxymidazolam <footnoteRef IDREF="t9fe"/>
                                                <br/>(substrate of CYP3A)</td>
                                             <td styleCode="Rrule"/>
                                             <td styleCode="Rrule">0.52<br/>(0.48, 0.57)</td>
                                             <td styleCode="Rrule">0.84<br/>(0.80, 0.88)</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20241125"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="1332f14a-681b-464a-a33b-f46c725d2b5d"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline italics">In Vitro Studies</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20241125"/>
                                 <component>
                                    <section>
                                       <id root="b68e9209-0737-4de6-a7c5-3e0fbdb6996c"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Cytochrome P450 (CYP) Enzymes</content>: Lenacapavir is not a substrate, inducer, or inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6. Lenacapavir is not an inducer of CYP3A4.</paragraph>
                                       </text>
                                       <effectiveTime value="20241125"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="15a7e551-2bc7-4f50-aee7-e98c736f2fb8"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Uridine diphosphate (UDP)-glucuronosyl transferase (UGT) Enzymes</content>: Lenacapavir is not an inhibitor of UGT1A1.</paragraph>
                                       </text>
                                       <effectiveTime value="20241125"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="dc67e2f4-c78a-4819-a273-91338a26205f"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Transporter Systems</content>: Lenacapavir is not an inhibitor of organic anion transporter 1 (OAT1), OAT3, organic cation transporter (OCT)1, OCT2, multidrug and toxin extrusion transporter (MATE) 1, or MATE 2-K. Lenacapavir is not a substrate of BCRP, OATP1B1, or OATP1B3.</paragraph>
                                       </text>
                                       <effectiveTime value="20241125"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.4">
                     <id root="f54b49d2-0358-49e3-af2a-40de18d63633"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>12.4 Microbiology</title>
                     <effectiveTime value="20241125"/>
                     <component>
                        <section>
                           <id root="a4242260-c8db-48ad-a1b9-de0650c6c3d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mechanism of Action</content>
                              </paragraph>
                              <paragraph>Lenacapavir is a multistage, selective inhibitor of HIV-1 capsid function that directly binds to the interface between capsid protein (p24) subunits in hexamers. Surface plasmon resonance sensorgrams showed dose-dependent and saturable binding of lenacapavir to cross-linked wild-type capsid hexamer with an equilibrium binding constant (K<sub>D</sub>) of 1.4 nM. Lenacapavir inhibits HIV-1 replication by interfering with multiple essential steps of the viral lifecycle, including capsid-mediated nuclear uptake of HIV-1 proviral DNA (by blocking nuclear import proteins binding to capsid), virus assembly and release (by interfering with Gag/Gag-Pol functioning, reducing production of capsid protein subunits), and capsid core formation (by disrupting the rate of capsid subunit association, leading to malformed capsids). </paragraph>
                           </text>
                           <effectiveTime value="20241125"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="4b21b8af-b886-4a4c-89a9-b06f240e82c5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Antiviral Activity in Cell Culture</content>
                              </paragraph>
                              <paragraph>Lenacapavir has antiviral activity that is specific to human immunodeficiency virus (HIV-1 and HIV-2). The antiviral activity of lenacapavir against laboratory and clinical isolates of HIV-1 was assessed in T-lymphoblastoid cell lines, PBMCs, primary monocyte/macrophage cells, and CD4<sup>+</sup> T-lymphocytes with EC<sub>50</sub> values ranging from 30 to 190 pM. Lenacapavir displayed antiviral activity in cell culture against all HIV-1 groups (M, N, O), including subtypes A, A1, AE, AG, B, BF, C, D, E, F, G with EC<sub>50</sub> values ranging from 20 and 160 pM. The median EC<sub>50</sub> value for subtype B isolates (n=8) was 40 pM. Lenacapavir was 15- to 25-fold less active against HIV-2 isolates relative to HIV-1.</paragraph>
                              <paragraph>In a study of lenacapavir in combination with representatives from the major classes of anti-retroviral agents (INSTIs, NNRTIs, NRTIs, and PIs), no antagonism of antiviral activity was observed.</paragraph>
                           </text>
                           <effectiveTime value="20241125"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="767d3115-d562-45dd-984f-a96299e57ba3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Resistance</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241125"/>
                           <component>
                              <section>
                                 <id root="7dd3987f-7079-40d9-af4b-85fa74c7367d"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">In Cell Culture</content>
                                    </paragraph>
                                    <paragraph>HIV-1 variants with reduced susceptibility to lenacapavir have been selected in cell culture. Resistance selections with lenacapavir identified 7 substitutions in capsid: L56I, M66I, Q67H, K70N, N74D/S, and T107N singly or in dual combination that conferred 4- to &gt;3,226-fold reduced phenotypic susceptibility to lenacapavir relative to wild-type (WT) virus. The M66I substitution alone or in combination conferred &gt;3,226-fold decreased susceptibility to lenacapavir in a single-cycle infectivity assay; substitutions Q67H and T107N, conferred 4- to 6.3-fold decreased susceptibility; K70N, N74D and Q67H/N74S conferred 22- to 32-fold decreased susceptibility; and L56I conferred 239-fold decreased susceptibility.</paragraph>
                                 </text>
                                 <effectiveTime value="20241125"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3a1c4549-4c19-4202-a941-81afcf809e7e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">In Clinical Trials</content>
                                    </paragraph>
                                    <paragraph>In CAPELLA, 31% (22/72) of heavily treatment-experienced participants met the criteria for resistance analyses through Week 52 (HIV-1 RNA ≥ 50 copies/mL at confirmed virologic failure [suboptimal virologic response at Week 4, virologic rebound, or viremia at last visit]) and were analyzed for lenacapavir resistance-associated substitution emergence. Lenacapavir resistance-associated capsid substitutions were found in 41% (n=9) of participants with confirmed virologic failure who had post-baseline capsid genotypic resistance data (n=22). The M66I capsid substitution was observed in 27% (6/22) of participants, alone or in combination with other lenacapavir resistance-associated capsid substitutions including Q67Q/H, Q67Q/H/K/N, K70K/R, K70N/S, N74D, N74N/H, A105T, and T107A. The other 3 participants with virologic failure had emergent lenacapavir resistance-associated capsid substitutions Q67K+K70H, Q67H+K70R+T107S, and Q67Q/H.</paragraph>
                                    <paragraph>Phenotypic analyses of the confirmed virologic failure isolates with emergent lenacapavir resistance-associated substitutions showed 6- to &gt;1428-fold decreases in lenacapavir susceptibility when compared to WT.</paragraph>
                                    <paragraph>Among the 9 participants with virologic failure who developed lenacapavir resistance-associated substitutions in capsid, 4 received SUNLENCA in combination with a background regimen with no fully active antiretrovirals based on the baseline genotypic and/or phenotypic resistance. Therefore, given the risk of developing resistance in situations of functional monotherapy, careful consideration should be given to having active drugs in addition to SUNLENCA in the treatment regimen.</paragraph>
                                    <paragraph>Four participants with virologic failure had emergent resistance substitutions to components of the optimized background regimen (OBR): emergent NRTI substitution M184I/V and NNRTI substitution K103N/Y with emtricitabine and doravirine plus atazanavir, bictegravir, and tenofovir alafenamide in OBR; emergent NNRTI substitution V106M from a mixture at baseline (in addition to lenacapavir resistance-associated substitutions M66I + T107A) with doravirine plus emtricitabine and ibalizumab in OBR; emergent NRTI substitutions K65R and S68N from mixtures at baseline (in addition to lenacapavir resistance-associated substitution M66I) with tenofovir alafenamide, plus emtricitabine, dolutegravir, darunavir/cobicistat, and rilpivirine in OBR; and emergent NRTI substitution K65K/R with tenofovir disoproxil fumarate plus darunavir/cobicistat, dolutegravir, and emtricitabine in OBR.</paragraph>
                                 </text>
                                 <effectiveTime value="20241125"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="67344137-d64a-4e4a-be50-8e2b543b8f20"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Oral Maintenance for Missed Injections</content>
                                    </paragraph>
                                    <paragraph>Of the 57 participants who received oral maintenance, 9 participants (5 participants in Cohort 1 and 4 participants in Cohort 2) met the criteria for resistance analysis. Six of these 9 participants had emergent lenacapavir resistance substitutions in capsid (Q67H [n=4], K70R or N [n=2], N74D or K [n=2], T107N [n=1]) with 4.5- to 393-fold decreased lenacapavir susceptibility. In addition, 2 participants had emergent resistance substitutions to darunavir in their optimized background regimen.</paragraph>
                                 </text>
                                 <effectiveTime value="20241125"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="19db8acd-4973-4b86-8f68-8d2b468a4a27"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Lenacapavir Resistance with Suboptimal Adherence to Other Antiretroviral Drugs in the Regimen </content>
                                    </paragraph>
                                    <paragraph>The development of lenacapavir-associated capsid resistance substitutions in 6 participants during the oral maintenance period was likely due to suboptimal adherence to the optimized background oral regimens that included dolutegravir and/or darunavir. After developing lenacapavir resistance, 5 of the 6 participants achieved HIV-1 RNA resuppression (HIV-1 RNA &lt; 50 copies/mL) while maintaining SUNLENCA treatment. With the emergence of lenacapavir resistance substitutions and decreased susceptibility to lenacapavir, it is unclear how much antiviral activity lenacapavir is contributing to the resuppression of HIV-1 RNA in these 5 participants.</paragraph>
                                    <paragraph>Thus, adherence to other antiretroviral drugs in the regimen should be optimized while the patient is receiving SUNLENCA. During SUNLENCA treatment, if suboptimal adherence to the oral antiretroviral regimen occurs with concurrent HIV-1 RNA viral load increases (<content styleCode="italics">i.e</content>., virologic failure), lenacapavir resistance should be assessed, and if detected, consideration should be given to discontinuing SUNLENCA treatment <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>, <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20241125"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="ab12bf32-312c-421d-b635-b50253ab7c00"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cross-Resistance</content>
                              </paragraph>
                              <paragraph>The antiviral activity in cell culture of lenacapavir was determined against a broad spectrum of HIV-1 site-directed mutants and patient-derived HIV-1 isolates with resistance to the four main classes of anti-retroviral agents (INSTI, NNRTI, NRTI, and PI; n=58), as well as to viruses resistant to the gp120-directed attachment inhibitor fostemsavir, the CD4<sup>+</sup>-directed post-attachment inhibitor ibalizumab, the CCR5 co-receptor antagonist maraviroc, and the gp41 fusion inhibitor enfuvirtide (n=42). These data indicated that lenacapavir remained fully active against all variants tested, thereby demonstrating a non-overlapping resistance profile. In addition, the antiviral activity of lenacapavir in patient isolates was unaffected by the presence of naturally occurring Gag polymorphisms and substitutions at protease cleavage sites.</paragraph>
                           </text>
                           <effectiveTime value="20241125"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="3e0e7522-c3eb-4000-aca1-826a843c8333"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20241125"/>
               <component>
                  <section ID="S13.1">
                     <id root="9962008c-2e61-4d5d-b45f-8e367e9e5a97"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20241125"/>
                     <component>
                        <section>
                           <id root="c52dc112-a3d9-4bfa-a3e8-a46cd12fa4c7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>Lenacapavir was not carcinogenic in a 6-month rasH2 transgenic mouse study in males or females at doses of up to 300 mg/kg/dose once every 13 weeks.</paragraph>
                              <paragraph>A 104-week carcinogenicity study was conducted in male and female rats at lenacapavir doses of 0, 102, 309, or 927 mg/kg by subcutaneous injection once every 13-weeks. A treatment-related increase in the incidence of malignant sarcoma at the injection site was observed in males and a treatment-related increase in combined benign fibroma and malignant fibrosarcoma at the injection site was observed in females, at the highest dose (927 mg/kg). This dose in rats resulted in an exposure approximately 34-times the human exposure at the RHD, based on AUC. These tumors are considered to be a secondary response to chronic tissue irritation and granulomatous inflammation, due to the depot effect of lenacapavir following subcutaneous injection. The clinical relevance of these findings are unknown.</paragraph>
                           </text>
                           <effectiveTime value="20241125"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="4be0243b-8992-471b-b4d2-aff98714e97f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mutagenesis</content>
                              </paragraph>
                              <paragraph>Lenacapavir was not mutagenic in a battery of <content styleCode="italics">in vitro</content> and <content styleCode="italics">in vivo</content> genotoxicity assays, including microbial mutagenesis, chromosome aberration in human peripheral blood lymphocytes, and in <content styleCode="italics">in vivo</content> rat micronucleus assays.</paragraph>
                           </text>
                           <effectiveTime value="20241125"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="294dbd23-86e6-4f7c-a6d5-2c8aa70b9457"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>There were no effects on fertility, mating performance or early embryonic development when lenacapavir was administered to rats at systemic exposures (AUC) 5 times the exposure to humans at the RHD of SUNLENCA.</paragraph>
                           </text>
                           <effectiveTime value="20241125"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="777d6be4-247b-478b-b964-77b046f08e01"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>The efficacy and safety of SUNLENCA in heavily treatment-experienced participants with multidrug resistant HIV-1 is based on 52-week data from CAPELLA, a randomized, placebo-controlled, double-blind, multicenter trial (NCT 04150068).</paragraph>
                  <paragraph>CAPELLA was conducted in 72 heavily treatment-experienced participants with multiclass resistant HIV-1. Participants were required to have a viral load ≥ 400 copies/mL, documented resistance to at least two antiretroviral medications from each of at least 3 of the 4 classes of antiretroviral medications (NRTI, NNRTI, PI and INSTI), and ≤ 2 fully active antiretroviral medications from the 4 classes of antiretroviral medications remaining at baseline due to resistance, intolerability, drug access, contraindication, or other safety concerns.</paragraph>
                  <paragraph>The trial was composed of two cohorts. Participants were enrolled into the randomized cohort (cohort 1, N=36) if they had a &lt; 0.5 log<sub>10</sub> HIV-1 RNA decline compared to the screening visit. Participants were enrolled into the non-randomized cohort (cohort 2, N=36) if they had a ≥ 0.5 log<sub>10</sub> HIV-1 RNA decline compared to the screening visit or after cohort 1 reached its planned sample size.</paragraph>
                  <paragraph>In the 14-day functional monotherapy period, participants in cohort 1 were randomized in a 2:1 ratio in a blinded fashion to receive either SUNLENCA or placebo, while continuing their failing regimen. This period was to establish the virologic activity of SUNLENCA. After the functional monotherapy period, participants who had received SUNLENCA continued on SUNLENCA along with an optimized background regimen (OBR); participants who had received placebo during this period initiated SUNLENCA along with an OBR.</paragraph>
                  <paragraph>Participants in cohort 1 had a mean age of 52 years (range: 24 to 71), 72% were male, 46% were White, 46% were Black, and 9% were Asian. 29% percent of participants identified as Hispanic/Latino. The mean baseline plasma HIV-1 RNA was 4.3 log<sub>10</sub> copies/mL (range: 2.3 to 5.4). 19% of participants had baseline viral loads greater than 100,000 copies/mL. The mean baseline CD4<sup>+</sup> cell count was 161 cells/mm<sup>3</sup> (range: 6 to 827). 75% of participants had CD4<sup>+</sup> cell counts below 200 cells/mm<sup>3</sup>. The mean number of years since participants first started HIV treatment was 24 years (range: 7 to 33); the mean number of antiretroviral agents in failing regimens at baseline was 4 (range: 1 to 7). The percentage of participants in the randomized cohort with known resistance to at least 2 agents from the NRTI, NNRTI, PI and INSTI classes was 97%, 94%, 78% and 75%, respectively. In cohort 1, 53% of participants had no fully active agents, 31% had 1 fully active agent, and 17% had 2 or more fully active agents within their initial failing regimen, including 6% of participants were who were receiving fostemsavir, which was an investigational agent at the start of the CAPELLA trial.</paragraph>
                  <paragraph>Participants in cohort 2 initiated SUNLENCA and an OBR on Day 1.</paragraph>
                  <paragraph>Participants in cohort 2 had a mean age of 48 years (range: 23 to 78), 78% were male, 36% were White, 31% were Black, 33% were Asian, and 14% of participants identified as Hispanic/Latino. The mean baseline plasma HIV-1 RNA was 4.1 log<sub>10</sub> copies/mL (range: 1.3 to 5.7). 19% of participants had baseline viral loads greater than 100,000 copies/mL. The mean baseline CD4<sup>+</sup> cell count was 258 cells/mm<sup>3</sup> (range: 3 to 1296). 53% of participants had CD4<sup>+</sup> cell counts below 200 cells/mm<sup>3</sup>. The mean number of years since participants first started HIV treatment was 19 years (range: 3 to 35); the mean number of antiretroviral agents in failing regimens at baseline was 4 (range: 2 to 7). The percentage of participants in the non-randomized cohort with known resistance to at least 2 agents from the NRTI, NNRTI, PI and INSTI classes was 100%, 100%, 83% and 64%, respectively. In cohort 2, 31% of participants had no fully active agents, 42% had 1 fully active agent, and 28% had 2 or more fully active agents within their initial failing regimen, including 6% of participants who were receiving fostemsavir, which was an investigational agent at the start of the CAPELLA trial.</paragraph>
                  <paragraph>The primary efficacy endpoint was the proportion of participants in cohort 1 achieving ≥ 0.5 log<sub>10</sub> copies/mL reduction from baseline in HIV-1 RNA at the end of the functional monotherapy period. The results of the primary endpoint analysis are shown in Table 10.</paragraph>
                  <table width="75%" ID="table10">
                     <caption>Table 10	Proportion of Participants Achieving a ≥ 0.5 log<sub>10</sub> Decrease in Viral Load at the End of the Functional Monotherapy Period in the CAPELLA Trial (Cohort 1)</caption>
                     <col width="54%" align="left" valign="middle"/>
                     <col width="23%" align="center" valign="middle"/>
                     <col width="23%" align="center" valign="middle"/>
                     <thead>
                        <tr>
                           <th styleCode="Lrule Rrule"/>
                           <th styleCode="Rrule">SUNLENCA <br/>(N=24)</th>
                           <th styleCode="Rrule">Placebo<br/>(N=12)</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">Proportion of Participants Achieving a ≥ 0.5 log<sub>10</sub> Decrease in Viral Load</td>
                           <td styleCode="Rrule">87.5%</td>
                           <td styleCode="Rrule">16.7%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule">Treatment Difference (95% CI)</td>
                           <td styleCode="Rrule" colspan="2">70.8% (34.9% to 90.0%) <footnote>p &lt; 0.0001</footnote>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>The results at Weeks 26 and 52 are provided in Table 11 and Table 12.</paragraph>
                  <table width="75%" ID="table11">
                     <caption>Table 11	Virologic Outcomes (HIV-1 RNA &lt; 50 copies/mL) at Weeks 26 <footnote>Week 26 window was between Days 184 and 232 (inclusive).</footnote> and 52 <footnote>Week 52 window was between Days 324 and 414 (inclusive). </footnote> with SUNLENCA plus OBR in the CAPELLA Trial (Cohort 1)</caption>
                     <col width="68%" align="left" valign="middle"/>
                     <col width="16%" align="center" valign="middle"/>
                     <col width="16%" align="center" valign="middle"/>
                     <thead>
                        <tr>
                           <th styleCode="Lrule Rrule"/>
                           <th styleCode="Botrule Rrule" colspan="2">SUNLENCA plus OBR<br/>(N=36)</th>
                        </tr>
                        <tr>
                           <th styleCode="Lrule Rrule"/>
                           <th styleCode="Rrule">Week 26</th>
                           <th styleCode="Rrule">Week 52</th>
                        </tr>
                     </thead>
                     <tfoot>
                        <tr>
                           <td align="left" valign="top" colspan="3">OBR = optimized background regimen</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">HIV-1 RNA &lt; 50 copies/mL</td>
                           <td styleCode="Rrule">81%</td>
                           <td styleCode="Rrule">83%</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">HIV-1 RNA ≥ 50 copies/mL<footnote>Includes participants who had ≥ 50 copies/mL in the Week 26 or 52 window; participant who discontinued early due to lack or loss of efficacy; participants who discontinued for reasons other than an adverse event (AE), death or lack or loss of efficacy and at the time of discontinuation had a viral value of ≥ 50 copies/mL.</footnote>
                           </td>
                           <td styleCode="Rrule" valign="top">19%</td>
                           <td styleCode="Rrule">14%</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">No virologic data in Week 26 or 52 Window</td>
                           <td styleCode="Rrule">0</td>
                           <td styleCode="Rrule">3%</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">  Discontinued Study Drug Due to AE or Death <footnote>Includes participants who discontinued due to AE or death at any time point from Day 1 through the time window if this resulted in no virologic data on treatment during the specified window.</footnote>
                           </td>
                           <td styleCode="Rrule">0</td>
                           <td styleCode="Rrule">0</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">  Discontinued Study Drug Due to Other Reasons <footnote>Includes participants who discontinued for reasons other than an AE, death or lack or loss of efficacy, e.g., withdrew consent, loss to follow-up, etc.</footnote> and Last Available HIV-1 RNA &lt; 50 copies/mL </td>
                           <td styleCode="Rrule">0</td>
                           <td styleCode="Rrule">3%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule">  Missing Data During Window but on Study Drug</td>
                           <td styleCode="Rrule">0</td>
                           <td styleCode="Rrule">0</td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="75%" ID="table12">
                     <caption>Table 12	Virologic Outcomes (HIV-1 RNA &lt; 50 copies/mL) by Baseline Covariates at Weeks 26 <footnote>Week 26 window was between Days 184 and 232 (inclusive).</footnote> and 52 <footnote>Week 52 window was between Days 324 and 414 (inclusive).</footnote> with SUNLENCA plus OBR in the CAPELLA trial (Cohort 1)</caption>
                     <col width="60%" align="left" valign="middle"/>
                     <col width="20%" align="center" valign="middle"/>
                     <col width="20%" align="center" valign="middle"/>
                     <thead>
                        <tr>
                           <th styleCode="Lrule Rrule"/>
                           <th styleCode="Botrule Rrule" colspan="2">SUNLENCA plus OBR<br/>(N=36)</th>
                        </tr>
                        <tr>
                           <th styleCode="Lrule Rrule"/>
                           <th styleCode="Rrule">Week 26</th>
                           <th styleCode="Rrule">Week 52</th>
                        </tr>
                     </thead>
                     <tfoot>
                        <tr>
                           <td align="left" valign="top" colspan="3">ARV = antiretroviral; DRV=darunavir; DTG=dolutegravir; INSTI = integrase strand-transfer inhibitor; OBR = optimized background regimen;</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">Age (Years)</td>
                           <td styleCode="Rrule" colspan="2"/>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">  &lt; 50</td>
                           <td styleCode="Rrule">100% (9/9)</td>
                           <td styleCode="Rrule">89% (8/9)</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">  ≥ 50</td>
                           <td styleCode="Rrule">74% (20/27)</td>
                           <td styleCode="Rrule">81% (22/27)</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">Gender</td>
                           <td styleCode="Rrule" colspan="2"/>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">  Male</td>
                           <td styleCode="Rrule">77% (20/26)</td>
                           <td styleCode="Rrule">77% (20/26)</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">  Female</td>
                           <td styleCode="Rrule">90% (9/10)</td>
                           <td styleCode="Rrule">100% (10/10)</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">Race</td>
                           <td styleCode="Rrule" colspan="2"/>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">  Black</td>
                           <td styleCode="Rrule">81% (13/16)</td>
                           <td styleCode="Rrule">75% (12/16)</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">  Non-Black</td>
                           <td styleCode="Rrule">84% (16/19)</td>
                           <td styleCode="Rrule">89% (17/19)</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">Baseline plasma viral load (copies/mL)</td>
                           <td styleCode="Rrule" colspan="2"/>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">  ≤ 100,000</td>
                           <td styleCode="Rrule">86% (25/29)</td>
                           <td styleCode="Rrule">86% (25/29)</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">  &gt; 100,000</td>
                           <td styleCode="Rrule">57% (4/7)</td>
                           <td styleCode="Rrule">71% (5/7)</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">Baseline CD4<sup>+</sup> (cells/mm<sup>3</sup>)</td>
                           <td styleCode="Rrule" colspan="2"/>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">  &lt; 200</td>
                           <td styleCode="Rrule">78% (21/27)</td>
                           <td styleCode="Rrule">78% (21/27)</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">  ≥ 200</td>
                           <td styleCode="Rrule">89% (8/9)</td>
                           <td styleCode="Rrule">100% (9/9)</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">Baseline INSTI resistance profile</td>
                           <td styleCode="Rrule" colspan="2"/>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">  With INSTI resistance</td>
                           <td styleCode="Rrule">85% (23/27)</td>
                           <td styleCode="Rrule">81% (22/27)</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">  Without INSTI resistance</td>
                           <td styleCode="Rrule">63% (5/8)</td>
                           <td styleCode="Rrule">88% (7/8)</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">Number of fully active ARV agents in the OBR</td>
                           <td styleCode="Rrule" colspan="2"/>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">  0</td>
                           <td styleCode="Rrule">67% (4/6)</td>
                           <td styleCode="Rrule">67% (4/6)</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">  1</td>
                           <td styleCode="Rrule">86% (12/14)</td>
                           <td styleCode="Rrule">79% (11/14)</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">  ≥ 2</td>
                           <td styleCode="Rrule">81% (13/16)</td>
                           <td styleCode="Rrule">94% (15/16)</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">Use of DTG and/or DRV in the OBR</td>
                           <td styleCode="Rrule" colspan="2"/>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">  With DTG and DRV</td>
                           <td styleCode="Rrule">83% (10/12)</td>
                           <td styleCode="Rrule">83% (10/12)</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">  With DTG, without DRV</td>
                           <td styleCode="Rrule">83% (5/6)</td>
                           <td styleCode="Rrule">83% (5/6)</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">  Without DTG, with DRV</td>
                           <td styleCode="Rrule">78% (7/9)</td>
                           <td styleCode="Rrule">89% (8/9)</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule">  Without DTG or DRV</td>
                           <td styleCode="Rrule">78% (7/9)</td>
                           <td styleCode="Rrule">78% (7/9)</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>In cohort 1, at Weeks 26 and 52, the mean change from baseline in CD4<sup>+</sup> cell count was 81 cells/mm<sup>3</sup> (range: -101 to 522) and 82 cells/mm<sup>3</sup> (range: -194 to 467), respectively.</paragraph>
                  <paragraph>In cohort 2, at Weeks 26 and 52, 81% (29/36) and 72% (26/36) of participants achieved HIV-1 RNA &lt; 50 copies/mL, respectively, and the mean change from baseline in CD4<sup>+</sup> cell count was 97 cells/mm<sup>3</sup> (range: -103 to 459) and 113 cells/mm<sup>3</sup> (range: -124 to 405), respectively.</paragraph>
               </text>
               <effectiveTime value="20241125"/>
               <component>
                  <section>
                     <id root="38d15efd-8747-441c-8134-14d9e845767c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Oral bridging</content>
                        </paragraph>
                        <paragraph>In CAPELLA across cohorts 1 and 2, 79% of participants (57/72) received SUNLENCA 300 mg once every 7 days as oral bridging. A total of 13, 29, and 15 participants started oral bridging following Weeks 26, 52, and 78 injections, respectively. The median (Q1, Q3) duration of oral bridging was 19 weeks (11, 22), and 12% (7/57) received oral bridging for at least 28 weeks.</paragraph>
                        <paragraph>In a post-hoc analysis, rates of virologic suppression and change from baseline in CD4<sup>+</sup> cell counts in the subset of patients who received oral bridging were consistent before and during the oral bridging period.</paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="7262805f-ac9e-43c5-9d93-0da3ee5f80dc"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20241125"/>
               <component>
                  <section>
                     <id root="8196d14d-e06d-4347-ae34-141a80b43762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">SUNLENCA tablets, 300 mg</content> are beige, capsule-shaped, and film-coated with "GSI" debossed on one side and "62L" on the other side. SUNLENCA tablets are available in a bottle and blister packs, packaged as follows:</paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                     <component>
                        <section>
                           <id root="510c1e5d-c810-4457-aef4-f1b8a8860295"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Bottle</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>SUNLENCA bottle contains 4 tablets (NDC 61958-3001-3). The bottle also contains a silica gel desiccant and polyester coil, and is closed with a child-resistant closure. Do not remove the desiccant packet. </item>
                              </list>
                              <paragraph>Keep bottle tightly closed.</paragraph>
                           </text>
                           <effectiveTime value="20241125"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="e0dee278-8b9c-45d1-b25c-a18e13f4e11f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Blister Packs</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>SUNLENCA 4-Tablets™ blister pack contains 4 tablets (NDC 61958-3001-1)</item>
                                 <item>SUNLENCA 5-Tablets™ blister pack contains 5 tablets (NDC 61958-3001-2)</item>
                              </list>
                              <paragraph>Within the blister packs, tablets are packaged in a clear blister film sealed to a foil lidding material. The blister card is fitted between two paperboard cards, and packaged with silica gel desiccant in a sealed child-resistant flexible laminated pouch.</paragraph>
                           </text>
                           <effectiveTime value="20241125"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="43b6d083-8ca0-42cb-9254-8d12cec8ec83"/>
                           <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                           <text>
                              <paragraph>Store bottle and blister packs at 20 °C – 25 °C (68 °F – 77 °F), excursions permitted to 15 °C – 30 °C (59 °F – 86 °F) (see USP Controlled Room Temperature).</paragraph>
                              <paragraph>Dispense and store only in original bottle or blister pack.</paragraph>
                           </text>
                           <effectiveTime value="20241125"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="c08472d8-fe19-4771-82f7-a091711a7a09"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">SUNLENCA injection</content> is packaged in one of two different injection kits containing the following:</paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                     <component>
                        <section>
                           <id root="20c399aa-1a0d-4231-82b0-90ee7aaf1558"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Vial access device injection kit (NDC 61958-3002-1):</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>2 single-dose clear glass vials, each containing sufficient volume to allow withdrawal of 463.5 mg/1.5 mL (309 mg/mL) of lenacapavir. The injection solution is sterile, preservative-free, clear, and yellow with no visible particles. Vials are sealed with a stopper and aluminium overseal with flip-off cap. </item>
                                 <item>2 vial access devices, 2 disposable syringes, and 2 injection safety needles for subcutaneous injection (22-gauge, ½ inch).</item>
                              </list>
                           </text>
                           <effectiveTime value="20241125"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="ac1416c2-b395-42a3-8272-9363961fd315"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Withdrawal needle injection kit (NDC 61958-3005-1):</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>2 single-dose clear glass vials, each containing sufficient volume to allow withdrawal of 463.5 mg/1.5 mL (309 mg/mL) of lenacapavir. The injection solution is sterile, preservative-free, clear, and yellow with no visible particles. Vials are sealed with a stopper and aluminium overseal with flip-off cap.</item>
                                 <item>2 disposable syringes, 2 withdrawal needles (18-gauge, 1.5 inch), and 2 injection safety needles for subcutaneous injection (22-gauge, ½ inch).</item>
                              </list>
                              <paragraph>The vial stoppers are not made with natural rubber latex.</paragraph>
                           </text>
                           <effectiveTime value="20241125"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="b0e4fea7-0348-43fb-a91d-a218e6fa9da1"/>
                           <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                           <text>
                              <paragraph>Store at 20 °C – 25 °C (68 °F – 77 °F), excursions permitted to 15 °C – 30 °C (59 °F – 86 °F).</paragraph>
                              <paragraph>Keep the vials in the original carton until just prior to preparation of the injections in order to protect from light. </paragraph>
                              <paragraph>Once the solution has been drawn into the syringes, the injections should be administered as soon as possible.</paragraph>
                              <paragraph>Discard any unused portion of the solution.</paragraph>
                           </text>
                           <effectiveTime value="20241125"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="d0478b50-2e3b-4d84-8013-af3c9e64f27f"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information).</paragraph>
               </text>
               <effectiveTime value="20241125"/>
               <component>
                  <section>
                     <id root="1ffd5ceb-23f8-4c97-a4d1-593959345b6f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Drug Interactions</content>
                        </paragraph>
                        <paragraph>SUNLENCA may interact with certain drugs; therefore, advise patients to report to their healthcare provider the use of any other prescription or non-prescription medication or herbal products, including St. John's wort, during treatment with SUNLENCA <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml> and <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>.</paragraph>
                        <paragraph>If SUNLENCA is discontinued, advise patients that SUNLENCA may remain in the body and affect certain other drugs for up to 9 months after receiving their last injection <content styleCode="italics">[see <linkHtml href="#S7.2">Drug Interactions (7.2</linkHtml>, <linkHtml href="#S7.3">7.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="da7f227c-d213-4f64-a4e7-0b28669de98a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Immune Reconstitution Syndrome</content>
                        </paragraph>
                        <paragraph>Advise patients to inform their healthcare provider immediately of any symptoms of infection, as in some patients with advanced HIV (AIDS), signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="7f046d04-2dcc-495a-8cd1-6d19953667b3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Adherence to SUNLENCA</content>
                        </paragraph>
                        <paragraph>Counsel patients about the importance of continued medication adherence and scheduled visits to maintain viral suppression and to reduce risk of loss of virologic response and development of resistance. Advise patients to contact their healthcare provider immediately if they stop taking SUNLENCA or any other drug in their antiretroviral regimen <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml> and <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="6135cc3d-160e-4dea-ad4d-59cfe51b08a1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Missed Dose</content>
                        </paragraph>
                        <paragraph>Inform patients that SUNLENCA can remain in the body for up to 12 months or longer after receiving their last injection. Advise patients to contact their healthcare provider if they miss or plan to miss a scheduled injection visit and that oral SUNLENCA therapy may be used for up to 6 months to replace missed injections. Advise patients that oral dosing should be used on an interim basis only and that the maintenance injection dosage should be resumed at the earliest possible opportunity <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml> and <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="58bfbd63-54a4-4bca-bee7-119fab2bda6a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Injection Site Reactions</content>
                        </paragraph>
                        <paragraph>Inform patients that injection site reactions (ISRs), such as swelling, pain, erythema, nodule, induration, pruritus, extravasation or mass, may occur. Nodules and indurations at the injection site may take longer to resolve than other ISRs and may be persistent. Instruct patients when to contact their healthcare provider about these reactions <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="e375a438-ee85-48d0-893f-3fbcb6b044f5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Registry</content>
                        </paragraph>
                        <paragraph>Inform patients that there is an antiretroviral pregnancy registry to monitor fetal outcomes of pregnant individuals exposed to SUNLENCA <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="63c57a61-820b-4092-86e2-c6db95016e85"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>
                        </paragraph>
                        <paragraph>Inform individuals with HIV-1 that the potential risks of breastfeeding include: (1) HIV-1 transmission (in infants without HIV-1), (2) developing viral resistance (in infants with HIV), and (3) adverse reactions in a breastfed infant similar to those seen in adults <content styleCode="italics">[see <linkHtml href="#S8.2">Use in Specific Populations (8.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="fcf20a52-2233-4b45-a06b-e84fd5259893"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>SUNLENCA is a trademark of Gilead Sciences, Inc., or its related companies. All other trademarks referenced herein are the property of their respective owners.</paragraph>
                  <paragraph>© 2024 Gilead Sciences, Inc. All rights reserved.</paragraph>
               </text>
               <effectiveTime value="20241125"/>
            </section>
         </component>
         <component>
            <section>
               <id root="749264d6-4db3-4118-b4b6-807ace350ac8"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <table width="100%">
                     <col width="42%" align="left" valign="top"/>
                     <col width="16%" align="left" valign="top"/>
                     <col width="21%" align="left" valign="top"/>
                     <col width="21%" align="left" valign="top"/>
                     <thead>
                        <tr>
                           <th styleCode="Lrule Rrule" colspan="4" align="center">PATIENT INFORMATION</th>
                        </tr>
                        <tr>
                           <th styleCode="Lrule" align="center" valign="bottom">SUNLENCA<sup>®</sup> (sun-LEN-kuh)<br/>(lenacapavir)<br/>tablets </th>
                           <th align="center"/>
                           <th styleCode="Rrule" align="center" valign="bottom" colspan="2">SUNLENCA<sup>®</sup> (sun-LEN-kuh)<br/>(lenacapavir)<br/>injection </th>
                        </tr>
                     </thead>
                     <tfoot>
                        <tr>
                           <td colspan="3" align="left">This Patient Information has been approved by the U.S. Food and Drug Administration.</td>
                           <td align="right">Revised: 11/2024        </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="4">										What is SUNLENCA? 										<br/>SUNLENCA is a prescription medicine that is used with other human immunodeficiency virus-1 (HIV-1) medicines to treat HIV-1 infection in adults:<list listType="unordered" styleCode="disc">
                                 <item>who have received HIV-1 medicines in the past, <content styleCode="bold">and</content>
                                 </item>
                                 <item>who have HIV-1 virus that is resistant to many HIV-1 medicines, <content styleCode="bold">and</content>
                                 </item>
                                 <item>whose current HIV-1 medicines are failing. Your HIV-1 medicines may be failing because the HIV-1 medicines are not working or no longer work, you are not able to tolerate the side effects, or there are safety reasons why you cannot take them.</item>
                              </list>HIV-1 is the virus that causes Acquired Immune Deficiency Syndrome (AIDS).<br/>It is not known if SUNLENCA is safe and effective in children.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="4">										Do not receive or take SUNLENCA if you also take certain other medicines called strong CYP3A inducers. Ask your healthcare provider if you are not sure. </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="4">										Before receiving or taking SUNLENCA, tell your healthcare provider about all your medical conditions, including if you: 										<list listType="unordered" styleCode="disc">
                                 <item>are pregnant or plan to become pregnant. It is not known if SUNLENCA can harm your unborn baby. Tell your healthcare provider if you become pregnant during treatment with SUNLENCA.<br/>												Pregnancy Registry: There is a pregnancy registry for women who take SUNLENCA during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk with your healthcare provider about how you can take part in this registry.</item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known whether SUNLENCA will pass to your baby in your breast milk. Talk with your healthcare provider about the following risks to your baby from breastfeeding during treatment with SUNLENCA:<list listType="unordered" styleCode="circle">
                                       <item>The HIV-1 virus may pass to your baby if your baby does not have HIV-1.</item>
                                       <item>The HIV-1 virus may become harder to treat if your baby has HIV-1.</item>
                                       <item>Your baby may get side effects from SUNLENCA.</item>
                                    </list>
                                 </item>
                              </list>										Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements, including St. John's wort. Some medicines may interact with SUNLENCA. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.<list listType="unordered" styleCode="disc">
                                 <item>You can ask your healthcare provider or pharmacist for a list of medicines that interact with SUNLENCA.</item>
                                 <item>												Do not start a new medicine without telling your healthcare provider. Your healthcare provider can tell you if it is safe to take SUNLENCA with other medicines.</item>
                                 <item>SUNLENCA may affect certain other medicines for up to 9 months after your last injection.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="4">										How should I receive and take SUNLENCA? 										<list listType="unordered" styleCode="disc">
                                 <item>Your SUNLENCA treatment will consist of injections and tablets.<list listType="unordered" styleCode="circle">
                                       <item>														SUNLENCA injections will be given to you by your healthcare provider under the skin (subcutaneous injection) in your stomach-area (abdomen). </item>
                                       <item>Take SUNLENCA tablets by mouth, with or without food.</item>
                                    </list>
                                 </item>
                                 <item>There are two options (Option 1 and Option 2) to start treatment with SUNLENCA. Your healthcare provider will decide which starting option is for you.<list listType="unordered" styleCode="circle">
                                       <item>If Option 1 is chosen:<list listType="unordered" styleCode="square">
                                             <item>On Day 1, you will receive 2 SUNLENCA injections and take 2 SUNLENCA tablets.</item>
                                             <item>On Day 2, you will take 2 SUNLENCA tablets.</item>
                                          </list>
                                       </item>
                                       <item>If Option 2 is chosen:<list listType="unordered" styleCode="square">
                                             <item>On Day 1 and Day 2, you will take 2 SUNLENCA tablets each day. </item>
                                             <item>On Day 8, you will take 1 SUNLENCA tablet.</item>
                                             <item>On Day 15, you will receive 2 SUNLENCA injections. </item>
                                          </list>
                                       </item>
                                    </list>
                                 </item>
                                 <item>After completing Option 1 or Option 2, you will receive 2 SUNLENCA injections every 6 months (26 weeks) from the date of your last injection.</item>
                                 <item>Stay under the care of a healthcare provider during treatment with SUNLENCA. It is important that you attend your planned appointments to receive your injections of SUNLENCA. 											</item>
                                 <item>If you miss or plan to miss your scheduled every 6 months injection of SUNLENCA, call your healthcare provider right away to discuss your treatment options.<list listType="unordered" styleCode="circle">
                                       <item>If you plan to miss a scheduled SUNLENCA injection, there is the option to temporarily take SUNLENCA tablets. You will take 1 SUNLENCA tablet by mouth 1 time every 7 days, until your injections resume.</item>
                                       <item>It is important to continue SUNLENCA treatment as your healthcare provider tells you. Missing SUNLENCA treatment may cause the HIV-1 virus to change (mutate) and become harder to treat (resistant).</item>
                                    </list>
                                 </item>
                                 <item>Tell your healthcare provider right away if you stop treatment with SUNLENCA or stop treatment with any other HIV-1 medicines. If you stop treatment with SUNLENCA you will need other medicines to treat your HIV-1 infection. If you do not take other HIV-1 medicines, the amount of virus in your blood may increase and the virus may become harder to treat. Call your healthcare provider right away to discuss your treatment options.</item>
                                 <item>If you take too many SUNLENCA tablets, call your healthcare provider or go to the nearest hospital emergency room right away.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="4">										What are the possible side effects of SUNLENCA?<br/>SUNLENCA may cause serious side effects, including: 										<list listType="unordered" styleCode="disc">
                                 <item>Changes in your immune system (Immune Reconstitution Syndrome) can happen when you start taking HIV-1 medicines. Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time. Tell your healthcare provider right away if you start having any new symptoms after starting your HIV-1 medicine.</item>
                                 <item>												Injection site reactions may happen when you receive SUNLENCA injections and may include swelling, pain, redness, skin hardening, small mass or lump, and itching. Hardened skin or lumps at the injection site usually can be felt but not seen. If you develop hardened skin or a lump, it may take longer than other reactions at the injection site to go away, and the injection site may not completely heal on its own. Tell your healthcare provider if you have any injection site reactions. </item>
                              </list>										The most common side effects of SUNLENCA are nausea and injection site reactions.<br/>These are not all of the possible side effects of SUNLENCA.<br/>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="4">										How should I store SUNLENCA tablets? 										<list listType="unordered" styleCode="disc">
                                 <item>Store SUNLENCA tablets at room temperature between 68 °F to 77 °F (20 °C to 25 °C).</item>
                                 <item>SUNLENCA bottle contains a desiccant packet to help keep your medicine dry (protect it from moisture). Keep the desiccant packet in the bottle. <content styleCode="bold">Do not eat the desiccant packet.</content>
                                 </item>
                                 <item>Keep SUNLENCA tablets in their original bottle or blister pack.</item>
                                 <item>Keep the bottle tightly closed. </item>
                              </list>										Keep SUNLENCA and all medicines out of reach of children. 									</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="4">										General information about the safe and effective use of SUNLENCA. 										<br/>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use SUNLENCA for a condition for which it was not prescribed. Do not give SUNLENCA to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about SUNLENCA that is written for health professionals.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="4">										What are the ingredients in SUNLENCA?<br/>Active ingredient: lenacapavir<br/>										Inactive ingredients: 										<br/>										SUNLENCA tablets: copovidone, croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, and poloxamer 407. The tablets are film-coated with a coating material containing iron oxide black, iron oxide red, iron oxide yellow, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.<br/>										SUNLENCA injection: polyethylene glycol 300 and water for injection.<br/>Manufactured and distributed by: Gilead Sciences, Inc. Foster City, CA 94404<br/>SUNLENCA is a trademark of Gilead Sciences, Inc., or its related companies. All other trademarks referenced herein are the property of their respective owners.<br/>© 2024 Gilead Sciences, Inc. All rights reserved. 215973-GS-004/IFU-001/IFU-WD-000<br/>For more information, call 1-800-445-3235 or go to www.SUNLENCA.com.</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20241125"/>
            </section>
         </component>
         <component>
            <section>
               <id root="a3b6989a-79ba-4d9b-a3e7-38082d7828b4"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 300 mg Tablet Blister Pack Pouch Carton</title>
               <text>
                  <paragraph>NDC 61958-3001-1</paragraph>
                  <paragraph>Sunlenca<sup>®</sup>
                     <br/>(lenacapavir) tablets<br/>300 mg per tablet</paragraph>
                  <paragraph>1 pouch containing 4 tablets</paragraph>
                  <paragraph>Each tablet contains: 300 mg of lenacapavir<br/>(present as 306.8 mg lenacapavir sodium).</paragraph>
                  <paragraph>Store at 20 °C - 25 °C (68 °F - 77 °F).</paragraph>
                  <paragraph>Dispense only in original container.</paragraph>
                  <paragraph>Recommended Dosage: See prescribing information.</paragraph>
                  <paragraph>KEEP OUT OF THE REACH OF CHILDREN</paragraph>
                  <paragraph>GILEAD</paragraph>
                  <paragraph>Manufactured for:<br/>Gilead Sciences, Inc.<br/>Foster City, CA 94404<br/>Made in Canada</paragraph>
                  <paragraph>© 2022 Gilead Sciences, Inc.</paragraph>
                  <renderMultiMedia referencedObject="MM6"/>
               </text>
               <effectiveTime value="20241125"/>
               <component>
                  <observationMedia ID="MM6">
                     <text>PRINCIPAL DISPLAY PANEL - 300 mg Tablet Blister Pack Pouch Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="sunlenca-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="99e26774-0cf4-4202-bb77-89e03d27a3b9"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 5 Tablet Blister Pack Pouch Carton</title>
               <text>
                  <paragraph>NDC 61958-3001-2</paragraph>
                  <paragraph>Sunlenca<sup>®</sup>
                     <br/>(lenacapavir) tablets<br/>300 mg per tablet</paragraph>
                  <paragraph>1 pouch containing 5 tablets</paragraph>
                  <paragraph>Each tablet contains: 300 mg of lenacapavir<br/>(present as 306.8 mg lenacapavir sodium).</paragraph>
                  <paragraph>Store at 20 °C - 25 °C (68 °F - 77 °F).</paragraph>
                  <paragraph>Dispense only in original container.</paragraph>
                  <paragraph>Recommended Dosage: See prescribing information.</paragraph>
                  <paragraph>KEEP OUT OF THE REACH OF CHILDREN</paragraph>
                  <paragraph>Talk to your healthcare provider before taking<br/>Sunlenca tablets.</paragraph>
                  <paragraph>Your healthcare provider will tell you when to take<br/>Sunlenca tablets.</paragraph>
                  <paragraph>GILEAD</paragraph>
                  <paragraph>Manufactured for:<br/>Gilead Sciences, Inc.<br/>Foster City, CA 94404<br/>Made in Canada</paragraph>
                  <paragraph>© 2022 Gilead Sciences, Inc.</paragraph>
                  <renderMultiMedia referencedObject="MM7"/>
               </text>
               <effectiveTime value="20241125"/>
               <component>
                  <observationMedia ID="MM7">
                     <text>PRINCIPAL DISPLAY PANEL - 5 Tablet Blister Pack Pouch Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="sunlenca-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="00ddcd9b-ad96-4ecc-bdca-4a0bb1953ceb"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 4 Tablet Bottle Label</title>
               <text>
                  <paragraph>NDC 61958-3001-3<br/>4 tablets</paragraph>
                  <paragraph>Sunlenca<sup>®</sup>
                     <br/>(lenacapavir) tablets<br/>300 mg per tablet</paragraph>
                  <paragraph>Talk to your healthcare provider <br/>before taking Sunlenca tablets.</paragraph>
                  <paragraph>Your healthcare provider will tell you <br/>when to take Sunlenca tablets.</paragraph>
                  <renderMultiMedia referencedObject="MM7a"/>
               </text>
               <effectiveTime value="20241125"/>
               <component>
                  <observationMedia ID="MM7a">
                     <text>PRINCIPAL DISPLAY PANEL - 4 Tablet Bottle Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="sunlenca-07a.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="981c5284-0b39-439d-b936-3acccd4f2326"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - Kit Carton</title>
               <text>
                  <paragraph>R<sub>x</sub> only<br/>NDC 61958-3002-1</paragraph>
                  <paragraph>Sunlenca<sup>®</sup>
                     <br/>(lenacapavir) injection</paragraph>
                  <paragraph>463.5 mg/1.5 mL (309 mg/mL)</paragraph>
                  <paragraph>For Subcutaneous Injection</paragraph>
                  <paragraph>Contents</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>2 x 1.5 mL lenacapavir single-dose vials</item>
                     <item>2 vial access devices</item>
                     <item>2 syringes</item>
                     <item>2 injection needles (22 gauge, 1/2 inch)</item>
                     <item>Prescribing Information</item>
                     <item>Instructions for Use</item>
                     <item>Patient Information</item>
                  </list>
                  <paragraph>Both 463.5 mg/1.5 mL (2 single-dose vials) must be<br/>administered to receive the 927 mg dose.</paragraph>
                  <paragraph>For Healthcare Professional administration only.</paragraph>
                  <paragraph>GILEAD</paragraph>
                  <renderMultiMedia referencedObject="MM8"/>
               </text>
               <effectiveTime value="20241125"/>
               <component>
                  <observationMedia ID="MM8">
                     <text>PRINCIPAL DISPLAY PANEL - Kit Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="sunlenca-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="1695358f-74a2-427b-babc-41b97fc289f8"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - Kit Carton - 3005</title>
               <text>
                  <paragraph>R<sub>x</sub> only<br/>NDC 61958-3005-1</paragraph>
                  <paragraph>Sunlenca<sup>®</sup>
                     <br/>(lenacapavir) injection</paragraph>
                  <paragraph>463.5 mg/1.5 mL (309 mg/mL)</paragraph>
                  <paragraph>For Subcutaneous Injection</paragraph>
                  <paragraph>Contents</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>2 x 1.5 mL lenacapavir single-dose vials</item>
                     <item>2 withdrawal needles (18 gauge, 1½ inch)</item>
                     <item>2 syringes</item>
                     <item>2 injection needles (22 gauge, ½ inch)</item>
                     <item>Prescribing Information</item>
                     <item>Instructions for Use</item>
                     <item>Patient Information</item>
                  </list>
                  <paragraph>Both 463.5 mg/1.5 mL (2 single-dose vials) must be<br/>administered to receive the 927 mg dose.</paragraph>
                  <paragraph>For Healthcare Professional administration only.</paragraph>
                  <paragraph>GILEAD</paragraph>
                  <renderMultiMedia referencedObject="MM9"/>
               </text>
               <effectiveTime value="20241125"/>
               <component>
                  <observationMedia ID="MM9">
                     <text>PRINCIPAL DISPLAY PANEL - Kit Carton - 3005</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="sunlenca-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>